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INTRODUCTION

Tuberculosis
Tuberculosis (TB) is the fourth leading cause of deaths attributable to infectious diseases
worldwide (World Health Organization 2005 [WHO]).1 Annually, it causes approximately 2
million deaths (Dye et al. 1999). The HIV pandemic has fueled TB-related mortality. Corbett and
colleagues (2003) estimated that in the year 2000, TB was responsible for 11% of all adult AIDS
deaths, and 11 million people in the world were coinfected with TB and HIV.
TB is an airborne disease caused by bacteria of the Mycobacterium tuberculosis complex
(MTB) – M. tuberculosis, M. bovis, M. africanum, M. microti, and M. canetti. MTB can affect
any part of the body,2 but its most common manifestation in humans is pulmonary disease.
Pulmonary tuberculosis symptoms include chest pain, coughing up blood (hemoptysis), persistent
cough, weight loss, night sweats, and fever. A chest radiograph of a pulmonary tuberculosis
patient demonstrates parenchymal infiltrates (fluid in the supportive tissue of the respiratory
system) or lesions in the lung cavity. Lymphadenopathy (swelling of the lymph nodes) may also
be present. Laboratory confirmation of tuberculosis is achieved by isolation of MTB from lung
mucus (sputum).
MTB is transmitted when infectious particles called droplet nuclei are aerosolized and
inhaled. Small in diameter (1-5µm), the particles can remain airborne for several hours (American
Thoracic Society [ATS] 2000). Pulmonary, pleural, and laryngeal TB disease are considered the

1

The top three leading causes of death attributable to communicable diseases are lower respiratory
infections, HIV/AIDS, and diarrhoeal diseases (WHO 2005).
2
Extrapulmonary forms of TB include laryngeal, lymphatic, neurological, spinal, and disseminated
(miliary).
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most potentially infectious forms of the disease because they are associated with expulsion of
droplets when a person with TB coughs, talks, sings, or sneezes. The likelihood of transmission
depends on the concentration of airborne droplets in the environment, the length of time a person
is exposed, and susceptibility of the exposed person to infection (ATS 2000; Frieden et al. 2003).
The WHO estimates that approximately one-third of the world’s population is infected with MTB
(Raviglione et al. 1995).

Latent Tuberculosis Infection
Asymptomatic MTB infection is called latent tuberculosis infection, or LTBI. In this
condition, MTB cannot be transmitted because the host’s immune system is able to stop the
bacteria from proliferating. If the effectiveness of the immune system decreases, the initial
infection can no longer be held in check, and active tuberculosis may develop. The risk of
progression to disease depends on the recency of infection and host factors such as age, immune
system status, and genetic susceptibility. Comorbid HIV infection, malnutrition, poorly controlled
diabetes, and/or other conditions that stress the immune system contribute to the development of
tuberculosis in persons with LTBI (ATS 2000; Frieden et al. 2003). The likelihood of developing
tuberculosis is highest within the first two years after infection (Ferebee 1970).

Global Perspective
In 2001, TB incidence was highest in Sub-Saharan Africa at 290 per 100,000 population
(Frieden et al. 2003). In contrast, the United States in 2001 experienced 5.6 TB cases per 100,000
(U.S. Centers for Disease Control and Prevention [CDC] 2002a). The WHO estimated that
worldwide, there were nine million new cases of TB in 2004 and that 80% of all TB patients live
in Africa or Asia (2006). In contrast, in the United States in 2004 there were 14,517 TB cases (4.9
per 100,000 population) (CDC 2005a). In 2006, TB incidence in the United States was 4.6 per
100,000 (CDC 2007a).

2

Although the burden of tuberculosis in the United States is small relative to that of other
nations, migration, increasing international travel, transitional economies, the emergence of drugresistant TB strains, and increasing incidence of HIV infection make TB elimination a public
health priority in low-incidence countries (Arnadottir 2001; CDC 2006a). TB is a global health
problem that requires a global solution (DeAngelis and Flanagin 2005; Brewer and Heymann
2005).
In 2000, the WHO issued Millennium Development Goals (MDGs) that are to be realized
by 2015. The sixth MDG is “Combat HIV/AIDS, malaria, and other diseases,” of which a target
is reversal of the global TB epidemic (Migliori et al. 2007). The WHO supports the Stop TB
Partnership, an international collaborative of organizations that developed and promotes the
Global Plan to Stop TB (Stop TB Partnership and WHO 2006). Global Plan targets include
reducing the prevalence of and deaths due to TB by 50% relative to 1990 by the year 2015, and
eliminating TB as a public health problem (< 1 case per million population) by the year 2050
(Dye et al. 2005; Stop TB Partnership and WHO 2006). The CDC is an active partner in this
initiative.

Tuberculosis Control in Connecticut
The CDC Division of TB Elimination (DTBE) promotes and administers the national
tuberculosis control and prevention program. In collaboration with partners like the ATS and
National Tuberculosis Controllers Association (NTCA), the DTBE issues national guidelines for
tuberculosis treatment and prevention. The DTBE also provides training and educational
materials to health care providers, conducts clinical research, and provides technical assistance to
State TB Control Offices (CDC 2007b). Nationwide tuberculosis surveillance is accomplished
through report of case information to the CDC using the Tuberculosis Information Management
System (TIMS) software application.

3

Located within the Infectious Diseases Section of the Public Health Initiatives Branch,
the Connecticut Department of Public Health (CTDPH) Tuberculosis Control Program (TBCP) is
responsible for TB control, prevention, and surveillance activities. It collaborates with local
health departments, visiting nurse associations, correctional managed healthcare, hospital-based
infectious disease clinics, community health centers, and private practice physicians. The TBCP
receives technical assistance from the DTBE medical officer for the New England Region
(Region I).3 In addition, the TBCP in partnership with the Connecticut TB Elimination Advisory
Committee (TEAC), a group of expert TB diagnosticians and care providers, issues
recommendations for the control of TB in congregate settings and TB screening in special
populations (TEAC 1994; 1995).
The TBCP is funded through a cooperative agreement with the CDC. Staff positions are
funded with the CDC grant and state monies. From federal fiscal year4 2000 to 2006, federal
funding of Connecticut tuberculosis control and prevention activities decreased from $875,100 to
$682,921 (CTDPH staff, personal communication). The largest amount of funding during this
period was fiscal year 2003 in which the CTDPH was awarded $1,186,440 for tuberculosis
control (OMB Watch 2008). The number of TBCP staff declined by 25% (12 to nine) between
the years 2000 – 2006. The TBCP employs one database developer in the CTDPH Information
Technology Section on a part-time basis, and the following full-time staff: one physician, two TB
case managers, two health program assistants, one nurse consultant, and one administrative
assistant for total of 7.5 staff in 2008. The current staffing level is 37.5% below that of the year
2000.

3

States of the New England Region are: Connecticut, Rhode Island, Massachusetts, New Hampshire,
Maine, and Vermont.

4

The Federal fiscal year starts on October 1 and ends on the following September 30. It is designated by
the year in which it ends (Office of Management and Budget 2006).
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The TBCP provides free medication for the treatment of TB and LTBI and
reimbursement for expenses related to the medical management of TB for the uninsured or
indigent. The TBCP also supplies health care providers with free purified protein derivative
(PPD) for tuberculin skin testing in high-risk populations and during contact investigations. TB
case management activities include review of hospital discharge plans and provision of directly
observed therapy (DOT) to TB cases by outreach workers. In addition, the TBCP generates
Connecticut TB incidence statistics and furnishes educational materials to health agencies and the
general public.
The first priority of the TBCP is treatment of individuals with tuberculosis. TB case
management is a multifaceted, labor-intensive process that includes DOT, monitoring of
laboratory findings, review of hospital discharge forms, and medical billing review. The second
priority of the TBCP is contact investigation, the process of identifying and screening persons
who have been exposed to infectious tuberculosis cases. Such contacts may have active disease,
or be at high risk of developing tuberculosis if they have LTBI.

Statement of the Problem
CDC regards Connecticut as a low TB incidence state (CDC 2002). Consistent with the
national trend, Connecticut TB cases are increasingly foreign born.5 Condren and colleagues
(2006) reported that 62% of the tuberculosis cases that occurred from 2000 to 2004 were from 62
different foreign countries. Of these TB cases, 46% were persons born in Asian, South American,
or Caribbean countries.
There were 638 TB cases in Connecticut between 2000 and 2005 (3.1 per 100,000
population). Of these reported TB cases, 452 (70.8%) were recorded as pulmonary disease in the

5

The CDC defines a foreign-born person as someone not born in the United States or its associated
territories. A U.S.-born person is born in the United States or its associated territories, or a person born
abroad with at least one U.S.-born parent (CDC 2006b).
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Tuberculosis Information Management System (TIMS). For Connecticut TB cases reported from
2000 – 2005, 1,294 contacts with LTBI were identified. Information on contacts was recorded in
the Tuberculosis Registry and Information Management System (TRIMS). The National
Tuberculosis Controllers Association and CDC recommend study of contact investigation data to
enhance control program performance (CDC 2005b). To date, TBCP has not conducted a
systematic review of contact investigation records, nor assessed the therapy completion rates
among contacts with LTBI.

Purpose of the Study
Healthy People 2010 delineates four goals toward tuberculosis elimination in the United
States, but only one pertains to latent infection. Healthy People 2010 goal 14-13 is to increase the
proportion of contacts and other high-risk persons with LTBI who complete a course of treatment
to 85% (U.S. Department of Health and Human Services [DHHS] 2000). The purpose of this
study is to examine Connecticut’s progress toward this Healthy People 2010 goal. This study
used data that were collected by CTDPH from 2000 to 2006 on Connecticut pulmonary
tuberculosis cases and their contacts with LTBI. Study results can inform decision-making about
the distribution of resources and program development for TB control and prevention efforts in
Connecticut. This is the first study of LTBI treatment completion rates among Connecticut
residents with LTBI who are contacts to pulmonary cases. Research objectives are to:
1) Assess contact investigation data collected in response to pulmonary tuberculosis cases that
occurred from 2000 to 2005.
2) Describe the characteristics of individuals with latent TB infection who were contacts to
pulmonary tuberculosis cases recorded from 2000 to 2005.
3) Calculate the treatment completion rates for these contacts; and
4) Identify predictors of LTBI treatment completion.
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LITERATURE REVIEW

Introduction
This literature review briefly summarizes the history and epidemiology of tuberculosis in
the United States and outlines the national strategies to eliminate TB. Specific action steps to
accelerate the decline of TB in the United States and contact investigation are outlined. Screening
for and the treatment of LTBI are described. Previous studies of contact investigation and LTBI
treatment completion are discussed. A list of abbreviations and glossary of terms are provided in
Appendix A.

Brief History of Tuberculosis
Tuberculosis has plagued mankind for centuries (Mackowiak et al. 2005). The Greeks
named it “phthisis” which means “consumption,” a reference to the way its victims wasted away.
There was much speculation about its cause, including: contagion, hereditary defect, degeneration
of the human race (Murray 2004), and vampirism (Sledzik and Bellantoni 1994). The so-called
“white plague” was a hallmark of nineteenth century Western civilization. Correlates of
industrialization, overcrowding and poor sanitation, contributed to its spread.
In 1882, German physician Robert Koch isolated M. tuberculosis, demonstrated that the
bacilli cause tuberculosis, and described methods to grow the bacteria and stain them for
microscopic identification (Kaufmann 2005).6 Confirmation of the bacterial etiology of
tuberculosis prompted new hygienic practices to reduce MTB transmission, inspired vaccine and
drug development, and spurred hopes that tuberculosis could be conquered.

6

During his career, Koch also identified Bacillus anthracis and Vibrio comma, causative agents of anthrax
and cholera, respectively (Kaufmann 2005; Murray 2004).

7

In the United States and Europe, isolation of the sick in order to control the spread of
disease was emphasized. Sanatoria where tuberculosis patients were given good nutrition, rest,
and exposure to fresh air were established. By 1945, there were 450 tuberculosis hospitals with
79,000 beds in the United States (Snider 1997). By the 1930s, the steady decline in the
tuberculosis rate led some to believe that at last, the “scourge of mankind” could be eliminated
once and for all. The discovery of antibiotics encouraged this belief.
In 1944, the antibiotic streptomycin was used to successfully treat TB. Other antituberculosis drugs were discovered during the next decade. Most notably, isoniazid (INH) was
discovered in 1952. Several clinical trials demonstrated its efficacy in preventing close contacts to
infectious TB cases from progressing to active disease (Ferebee 1970). As chemotherapy became
widespread, TB sanatoria began to disappear, and ambulatory care became the standard of care
(Snider 1997).

Tuberculosis in the United States, 1952 - 2006
In 1952, TB became a nationally notifiable disease that was reportable to the United
States Public Health Service Tuberculosis Control Program, the precursor of the CDC DTBE.
Nationwide tuberculosis surveillance began in 1953 (Schneider et al. 2005). In that year, there
were 53 TB cases per 100,000 population (CDC 2005). By 1971, this rate had dropped to
approximately 17 per 100,000 population (Addington 1979). In 1972, federal categorical funding
of TB control activities was terminated and tuberculosis-related actives became eligible for
funding through federal block grants (Binkin et al. 1999). As TB incidence decreased nationwide,
the public health infrastructure surrounding its control became a victim of its success and was
gradually dismantled (Frieden et al. 1995; U.S. Congress 1993).
From 1953 to 1984, TB incidence declined at an annual average rate of 5.8% each year to
9.4 cases per 100,000 nationwide (Navin et al. 2002). The decline was partially attributed to
expanded treatment assurance and contact investigation efforts in high-incidence areas (CDC
8

1985). The decline stalled in 1985, when the number of TB cases reported to CDC was 22,001,
only 54 cases less than count for the previous year for a rate of 9.3 per 100,000 (CDC 1986a).
More cases than expected occurred in all age groups, all races, and both sexes.
From 1985 to 1992, during the initial decade of the HIV/AIDS epidemic in the United
States (CDC 2006b), the number of reported TB cases increased by 20.1%. Increases in 1992
were largest among blacks, Hispanics, and Asian/Pacific Islanders; the foreign born; and persons
aged 25-44 years (CDC 1993). Multidrug-resistant (MDR) tuberculosis emerged as a threat to TB
control (Simone and Dooley 1998; CDC 2006a).7
Although there was an agonistic relationship between AIDS and TB mortality (CDC
1986b), HIV infection alone could not explain the excess deaths observed. Decrease in public
health efforts to control TB, increasing poverty and homelessness, immigration to the United
States from countries with high TB prevalence, and overcrowded congregate settings (e.g.,
prisons) also contributed to the resurgence of tuberculosis in the United States (CDC 1993;
Frieden et al. 1995; Schneider et al. 2005).
In 1989 the CDC and the Advisory Council for the Elimination of Tuberculosis (ACET)
issued A Strategic Plan for the Elimination of Tuberculosis in the United States. ACET defined
TB elimination as an incidence rate of less than one case per million population by the year 2010,
with an interim target of 3.5 cases per 100,000 population by the year 2000 (CDC 2002b). The
strategic plan identified the following actions to eliminate tuberculosis: 1) more effective use of
prevention and control methods; 2) development of new technologies for TB diagnosis, treatment,
and prevention; and 3) more rapid inclusion of the new technologies in clinical and public health
practice.

7

MDR tubercle bacilli are not killed by the first-line TB treatment drugs (isoniazid [INH] and rifampin
[RIF]) and require use of more toxic and costly second-line drugs (SLDs).
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Eventually, the TB resurgence was reversed by a return to categorical federal funding of
TB control efforts and the framework provided by the national strategic plan. Directly observed
therapy, wherein the tuberculosis patient is observed taking each dose of medication to ensure
treatment adherence and completion, was instituted. The control of TB spread in congregate
settings, particularly prisons, was enhanced by improvements in screening, isolation, and followup. Advances in anti-tuberculosis drugs and regimens, and HIV care also contributed to TB
incidence reduction (CDC 2005c).
In 1999, the ACET reevaluated the national strategic plan in response to the changing
epidemiology of TB in the United States. The ACET recommended: 1) use of prevention, control
and elimination strategies that are tailored to local TB epidemiology; 2) establishment of new
partnerships to more effectively reach populations at risk for MTB infection; 3) enhancement of
current tools for TB prevention and control; 4) development of new tools for elimination (e.g.,
vaccine, DNA fingerprinting of MTB strains); 5) recommitment to the global effort against TB;
and 6) support of broad-based efforts for TB prevention and control at the local, state, and
national levels (CDC 1999).
TB control and prevention strategies under the national strategic plan resulted in the
steady decline of new cases nationwide. The TB case rate in the United States was 4.6 per
100,000 population in 2006. But while the national TB rate has fallen, the pace at which it has
done so has slowed. Foreign-born persons and racial/ethnic minority populations are
disproportionately affected by TB in the United States. In 2002, 50% or more of the TB cases in
22 states were among the foreign born. In seven states, more than 70% of the cases were among
foreign-born persons. Among the foreign born, the rate of tuberculosis was 8.7 times higher than
that for native-born persons in 2005 (CDC 2006c). By the end of 2006, the TB rate in the foreign
born increased to 21.9 per 100,000, or 9.5 times that of the rate for the U.S.-born. In 2006, TB
rates among Hispanics, blacks, and Asians were 7.6, 8.4, and 21.2 times higher than rates among
10

whites, respectively (CDC 2007a). Moreover, persons not born in the U.S. are more likely to
develop MDR-TB. In a study of California TB cases from 1994 – 2003, Granich and colleagues
(2005) determined that MDR-TB incidence was significantly higher among foreign-born TB
cases than among U.S.-born TB cases (3.5 versus 0.2 cases per 100,000).

Ending Neglect
In 2000, the Institute of Medicine (IOM) published Ending Neglect, in which it
recommended five strategies for TB elimination in the United States. Among them is accelerating
the decline of tuberculosis by limiting the spread of disease from infectious cases to their contacts
and preventing the development of tuberculosis in people with LTBI. In 2003, the United States
Federal Tuberculosis Task Force created a plan in response to the IOM recommendations. Among
the five strategies to “limit the spread of TB from infectious patients to their contacts” are the
development of national guidelines for contact investigations, and epidemiologic and behavioral
studies of contact investigations to determine why people do not complete LTBI therapy (Federal
Tuberculosis Task Force 2003).

Contact Investigation
Individuals who were potentially exposed to an infectious TB case are called contacts.
They are identified through a process called contact investigation, the goals of which are to detect
secondary tuberculosis cases and identify persons with LTBI. Because approximately 30% of
contacts will become infected with MTB (IOM 2000), and one percent of them will have already
progressed to active tuberculosis by the time that the index case has been detected, contact
identification is a high priority. Nonetheless, contact investigation is second to TB case
identification and characterization, and dependent on availability of program resources.
In 2005, the NTCA and the CDC released Guidelines for the Investigation of Contacts of
Persons with Infectious Tuberculosis. These comprehensive recommendations address 13 areas:
1) the decision to conduct a contact investigation; 2) investigation of the index patient (i.e. TB
11

case); 3) assigning priorities to contacts based on exposure; 4) diagnostic screening of contacts; 5)
treatment of contacts with LTBI; 6) when to expand an investigation; 7) communications; 8) data
management and evaluation; 9) confidentiality and consent; 10) staffing and training; 11)
investigations in special circumstances; 12) source-case investigations; and 13) other topics such
as social network analysis, new blood tests for MTB infection, and cultural competency. When to
initiate an investigation, contact prioritization, diagnostic screening of contacts, and treatment of
LTBI are discussed below.
According to the NTCA and CDC guidelines, a contact investigation should be
considered for every confirmed case of pulmonary, pleural, or laryngeal TB. An investigation is
recommended when the risk of tuberculosis transmission is high. Risk assessment entails
examining the anatomical site of the disease, testing sputum or respiratory secretions for the
presence of infectious MTB, and observing behaviors such as coughing and sneezing that can
aerosolize infectious droplets. Accordingly, the highest priority for contact investigation is a
cavitary pulmonary case with AFB-positive sputum smear. 8
Once the decision to initiate a contact investigation has been taken, the contacts to screen
for active disease and latent infection are identified. This is achieved through careful interview of
the index case to obtain information on the identity and location of contacts, and the nature of the
relationship between contacts and the index case (Wolman et al. n.d.). Next, contacts are
prioritized for screening for active disease and LTBI. Risk of infection may be high, medium, or
low. “Priorities for contact investigation are determined on the basis of the characteristics of the
index patient, susceptibility and vulnerability of contacts, and circumstances of the exposures”
(CDC 2005b: 11).

8

A microbiological characteristic of MTB is that the organism retains chemical stains in cell walls even
after washing in acid.
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Traditionally, the term “close contact” has been used to designate a person who
experienced frequent or prolonged exposure to the infectious index case (e.g., household
member), while the term “casual contact” has been used to describe an individual with less
frequent interaction with the index case (e.g., non-household family member). However, using
these designations for contact investigation is problematic because they can become conflated
with the social meanings of “close” and “casual.” For example, an index case with infectious
cavitary pulmonary TB may have a “casual” social relationship with coworkers, but sharing a
small enclosed space with them while coughing throughout the workday makes the coworkers
high risk contacts.
The characteristics of the contact, particularly age and immune system status, contribute
to risk of infection. Children under five years old and people with low immune system function
are at especially high risk of rapid progression to active disease when infected with MTB (ATS,
CDC, and Infectious Diseases Society of America [IDSA] 2003; Schneider et al. 2005).
Underweight (less than 10% of ideal), diabetes mellitus, silicosis, chronic renal failure,
gastrectomy, jejunoileal bypass, solid organ transplantation, carcinoma of the head or neck,
intravenous drug use, and HIV infection are associated with two to 162 times greater risk of
developing active TB compared to the general population. Persons using corticosteroids or other
medications that suppress the immune system for prolonged periods are also at greater risk of
developing TB (CDC 2000).
Special populations at increased risk of developing TB are persons in correctional
facilities and the homeless. Living in congregate settings conducive to TB transmission and the
high prevalence of HIV infection increase the risk of progression to active TB in these groups
(Sepkowitz et al. 1995; Paul et al. 1993). Unrecognized transmission of TB in correctional
facilities can result in decreased recognition of contacts with LTBI who are in need of treatment
to prevent the development of active TB (MacIntyre et al. 1999). Homeless individuals,
13

particularly those with HIV infection or who are classified as nonwhite are at high risk for rapid
progression to active TB (Moss et al. 2000). Moreover, other TB risk factors such as substance
abuse and history of incarceration overlap with persistent homelessness (Haddad et al. 2005).
Another group at higher risk for developing TB is the foreign born, especially individuals from
high-TB incidence countries. These persons have the greatest risk of developing active TB within
their first five years of immigration to the U.S. (Patel et al. 2007).
With regard to circumstances of exposure, duration and environment type are considered.
The NTCA and CDC guidance recommends that health departments establish environmental
exposure duration limits based on their local experience. For example, spending eight hours in a
small, windowless, poorly ventilated office with a person who has cavitary pulmonary disease
and who is coughing, presents more risk of exposure to infectious droplets than spending eight
hours with the same person on opposite sides of a warehouse with large open windows and
ceiling fans.
In general, high risk contacts to infectious tuberculosis cases are: household members,
children under five years old, persons with low immune system function, individuals exposed in
congregate settings (e.g., prison, dormitory), persons exposed during medical procedures that
aerosolize infectious secretions (e.g., bronchial lavage), and persons with prolonged
environmental exposure.

Screening for Latent TB Infection
In the contact investigation process, screening of contacts for tuberculosis disease or
latent infection involves a tuberculin skin test (TST) and chest radiograph. Usually, TSTs in the
United States are performed using the Mantoux method. This entails injection of a purified
protein derivative (PPD), tuberculin, under the top layer of skin of the medial portion of the
forearm.
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PPD is a mixture of antigens that produces a delayed-type hypersensitivity reaction and
indicates cell-mediated immune response against Mycobacteria (Whalen 2005). In the case of
MTB infection, a firm bump, an induration, will result 48 to 72 hours at the PPD injection site.
The induration is measured and compared to cutoff values established by the CDC and the ACET
to determine if the reaction constitutes evidence of MTB infection (CDC 2000; CDC 2005c). An
induration greater than or equal to 5 millimeters (mm) is considered positive in persons with
recent contact to an active TB case.
While the TST is cost-effective, safe, and easy to administer, it has several drawbacks
(Glassroth 2005; Whalen 2005), including: 1) the 48- to 72-hour period between administration
and measurement requires a return visit; 2) interobserver variability in result interpretation; 3)
false-positive results occur because PPD cross-reacts with antigens in non-MTB Mycobacteria
including M. bovis, which is used in the vaccine Bacille Calmette Guérin (BCG);9 4) poor
repeatability – the size of the induration in subsequent tests varies; and 5) anergy, when a
negative PPD occurs in persons with attenuated cell-mediated immune response (e.g.,
HIV/AIDS, end-stage renal disease), even when there is actual active or latent infection (Jones
1996; Perlman et al. 1999; Shankar et al. 2005).
Another test for MTB infection is the QuantiFERON®-TB Gold (QFT-G) test that was
approved by the United States Food and Drug Administration (USDA) in 2005. QFT-G is an
enzyme-linked immunosorbent assay (ELISA) test that detects the release of interferon-gamma
(IFN-γ) in blood associated with the presence of M. tuberculosis and pathogenic M. bovis bacteria

9

In 1908, Albert Calmette and Camille Guérin of France began development of a TB vaccine using an
isolate of M. bovis. They developed a weakened strain of the initial isolate that would not cause disease, but
provoke sufficient immune response to MTB to offer protection. BCG was first administered to an infant in
1921 whose mother had died of TB (Kaufmann 2005). As of 2003, 158 (82.3%) of World Health
Organization Member States routinely administer BCG at birth (WHO 2006). BCG can prevent
neurological TB in children; however, its protective efficacy in adolescents and adults has been described
as “variable and equivocal” (CDC 1996: 1).
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strains. A blood test that can be processed within 24 hours, the QFT-G has greater specificity than
the PPD used in TSTs. Vaccination with BCG does not affect the result. The QFT-G may be used
in place of a TST (CDC 2005d).
A posterior-anterior chest radiograph is indicated for persons who have a positive TST or
QFT-G result, or those who have symptoms consistent with active TB disease. If a person has a
positive TST or QFT-G test result, no signs or symptoms of active disease, and a normal chest
radiograph, s/he is classified as having LTBI. If a person has evidence of MTB infection, signs
and symptoms of active disease and an abnormal chest radiograph, s/he is classified as a suspect
TB case (CDC 1997).

Treatment for Latent TB Infection
Table 1, adapted from Targeted Tuberculin Testing and Treatment of Latent Tuberculosis
Infection (CDC 2005e: 2), lists the preferred and alternative prophylaxis regimens for treatment
of LTBI. At least once per month, a person receiving treatment for LTBI should be evaluated by a
clinician for signs of active tuberculosis, evidence of liver damage (i.e. hepatitis), and the status
of treatment adherence (CDC 2004).
The standard treatment regimen for LTBI in adults is 5 milligrams (mg) per kilogram
(kg) of isoniazid (INH) daily for nine months. INH taken daily for six months does not confer as
much protection from progression to disease as the nine-month regimen, but “two-thirds of the
preventive value of isoniazid therapy is achieved after 6 months” (International Union Against
Tuberculosis [IUAT] Committee on Prophylaxis 1982: 562). Four months of rifampin (RIF) is an
alternative to nine months of INH (ATS, CDC, and IDSA 2000). A short, two to three-month
course of rifampin and pyrazindamide (RIF+PZA) was recommended in the year 2000 for
persons with HIV (ATS, CDC, and IDSA 2000). However, severe liver damage was associated
with the combination (van Hest et al. 2004; Priest et al. 2004) and the recommendation for its use
for the treatment of LTBI was formally cautioned in 2003 (CDC 2003). Some studies have
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demonstrated the success of a three to four-month regimen of INH in combination with RIF for
the treatment of LTBI (Paloma Geijo et al. 2007; Spyridis et al. 2007); however, the CDC and the
ATS have not recommended this regimen.

Table 1. LTBI Treatment Regimens

Daily Dose

Duration
(months)

Regimen Type

Isoniazid

Adult: 5 mg/kg
Child: 10-20 mg/kg
Maximum: 300 mg

9

Preferred

Isoniazid

Adult: 5 mg/kg
Maximum: 300 mg

6

Alternative

4

Alternative

2

Recommendation
as an alternative
discontinued in
2003

Drug

Rifampin

Rifampin
& Pyrazindamide

Adult: 10 mg/kg
Child: 10-20 mg/kg
Maximum: 600 mg
Adult: 10 mg/kg
Maximum: 600 mg
&
Adult: 20 mg/kg
Maximum: 2,000 mg

Contact Investigations and LTBI Treatment Completion
Previous studies of contact investigations show that treatment of LTBI is most frequently
recommended for children and high-risk contacts, and that it is dependent on the availability of
medication to contacts, a continuous therapy course, access to health care, and contact country of
birth.
Marks and colleagues (2000) described the outcomes of contact investigations in urban
areas. They abstracted clinic records from of a representative sample of 1,080 pulmonary TB
cases with positive sputum smears that were reported to CDC from July1996 to June 1997. They
identified 6,225 persons as close contacts. Of these, 1,381 (22%) with positive tuberculin skin
tests were recommended to complete a six-month LTBI treatment regimen. While 1,277 (92.5%)
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of these began treatment, only 707 of them completed, for a treatment completion rate of 55.4%.
Using multiple regression analysis that controlled for race, ethnicity, and foreign birth, Marks and
colleagues found that tuberculin skin test positive (TST+) contacts who received DOT were more
likely to complete treatment than others, and that interruptions in treatment course contributed to
noncompletion of therapy.
Reichler and colleagues (2002a) described treatment completion rates among recently
infected contacts to TB cases after reviewing the 1996 TB case records of five state health
departments in the United States. The 360 culture-positive pulmonary identified had 2, 267
contacts who were screened for active TB and LTBI. Of these contacts, 630 (28%) were TST+
and 447 (71%) were recommended to get treatment for LTBI infection. Of those for whom
treatment was recommended, 398 (89%) began it; however, only 203 (51%) completed a LTBI
treatment regimen greater than 6 months. Treatment completion rates varied widely between
health departments (range 20 – 69%). The overall treatment completion rate was 45.4% (203 of
447). Treatment for LTBI was more likely to be recommended for skin test converters, contacts
less than 15 years old, close contacts, and contacts of smear-positive TB cases.
A retrospective cohort study conducted by Parsyan and colleagues (2006) examined the
acceptance and completion of LTBI treatment among 2,621 TB clinic attendees. Of the 1,723
persons offered a 6-month treatment regimen, 1571 (91.2%) consented; however, only 607
(38.6%) completed treatment. Of the 965 who did not complete LTBI treatment, 517 (54%)
discontinued it before the end of the first month. The researchers concluded that the strongest
predictor of LTBI treatment noncompletion in their sample at a Boston, Massachusetts’s clinic
was birth in Haiti or the Dominican Republic. They proposed that findings may reflect cultural or
behavioral determinants related to country of birth or availability of social and medical services to
the immigrant communities in the clinic’s service area.
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METHODS

Study Design
This retrospective study examines Connecticut’s progress toward the Healthy People
2010 objective to increase the proportion of persons with LTBI who complete preventive therapy
to 85%. Data on persons with latent tuberculosis infection, who were identified as contacts to
pulmonary TB cases in Connecticut from 2000 to 2005, were analyzed.
This study will help to answer the following questions:
1) How complete are the contact investigation data that constitute initial information on contacts
to pulmonary cases?
2) What is the overall LTBI treatment completion rate among contacts to Connecticut
pulmonary TB cases?
3) What is the drug regimen-specific LTBI treatment completion rate among contacts to
Connecticut pulmonary TB cases?
4) How are demographic characteristics (e.g., age, race, gender) associated with the likelihood
of LTBI treatment completion?
5) How are tuberculosis risk factors (e.g., immunosuppression, substance abuse) associated with
the likelihood of LTBI treatment completion?
6) Which demographic characteristics and tuberculosis risk factors are the strongest predictors
of LTBI treatment completion?
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Overview of Data Sources
Reporting forms
Connecticut General Statutes § 19a-2a, and §s 19a-36-A4 of the Connecticut Public
Health Code mandate that medical providers and clinical laboratories notify the CTDPH of
reportable diseases/conditions. Annually, the CTDPH publishes the List of Reportable Diseases
and Laboratory Findings and distributes reporting forms to Connecticut health care providers and
clinical laboratories. The primary reporting forms are the Reportable Disease Confidential Case
Report Form PD-23 (Appendix B) and the Laboratory Report of Findings Form OL-15C
(Appendix C). These are triplicate, carbon-interleaved forms. One copy is retained for the
patient’s medical record and the others are mailed to the CTDPH and the local health department
(LHD) with jurisdiction over the town where the patient lives.
Category I reportable diseases must be reported immediately by telephone upon
recognition or strong suspicion of disease. Category II reportable diseases must be reported by
mail within 12 hours of recognition or strong suspicion. Tuberculosis is a Category I reportable
disease. HIV infection in a person with latent TB infection is a Category II reportable disease.
Thus, Connecticut law does not require health care providers to report LTBI unless the patient has
comorbid HIV infection. Contacts identified during contact investigations are reported to the
TBCP via the Tuberculosis Contact Investigation Report Form (TB-5), which records some
contact demographics, TST results, and medical screening information (Appendix D). In addition,
because the CTDPH provides free medications to treat persons with LTBI, health care providers
are encouraged to report LTBI.
The TBCP requests completion of a Tuberculosis Surveillance Report (TB-86) for each
person with TB or LTBI (Appendix E). The treatment courses of all persons with TB or LTBI are
documented on the Tuberculosis Tracking and Follow-up Case Report Form (TB-32) (Appendix
F). The TB-32 should be submitted at least once per month to track clinical monitoring for
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medication side effects and coordinate the shipment of medication to the health care provider.
Like the PD-23 and OL-15C, the TB-86, and TB-32 are triplicate, carbon-interleaved forms that
the TBCP mails to providers’ offices upon request. The TB-5 is supplied to local health
departments and other agencies (e.g., visiting nurse association) that conduct contact
investigations. Table 2 summarizes the reporting forms that provide data on persons with latent
tuberculosis infection.
Table 2. Reporting Forms Providing Data on Persons with LTBI
Name

Abbreviation

Purpose

Tuberculosis Surveillance Report

TB-86

Initial report of
active TB or LTBI

Tuberculosis Contact Investigation
Report Form

TB-5

Record information collected
during a contact investigation

Tuberculosis Tracking and Follow-up
Case Report Form

TB-32

Record information on
therapeutic course

Electronic databases and patient charts
The data recorded on the reporting forms are entered into one of two electronic databases.
Information on active TB cases is recorded in a CDC-developed database called the Tuberculosis
Information Management System (TIMS). TIMS enables electronic transmission of TB case
information to the DTBE. Each TB case is assigned a unique identification number that
corresponds to a paper chart that is stored at CTDPH in a secure location. In addition to outreach
worker notes and clinician notes, TB case files contain the following reporting forms: the OL15C, TB-86, TB-32s, and TB-5s.
Data on persons with LTBI are entered into the Tuberculosis Registry and Information
Management System (TRIMS). Records are indexed by last name, first name, and date of birth.
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Paper files are maintained for each person with LTBI and stored in a secure area. LTBI files
contain the TB-86 and TB-32s.
The pulmonary case list
Through TRIMS, information on TB cases in TIMS can be accessed. Linkage of the
databases by TB case identification number enables the query of information on cases and their
related contacts. Using TRIMS, the pulmonary case list was generated by a TBCP staff person for
this study. 10 Four hundred and fifty-two pulmonary TB cases were listed from 2000 to 2005. 11
The following variables on these cases were collected: case identification number, year of report,
age, race, foreign-born status, country of origin, city of residence, and county of residence.
EXTRACT
The TRIMS application developer, using a complex query, extracted information on
persons with LTBI from TRIMS for this study. These data, hereafter referred to as EXTRACT,
were used to describe the characteristics and treatment status of persons with LTBI who were
contacts to pulmonary TB cases. EXTRACT was also used to determine treatment completion
rates. EXTRACT variables were: source case number,12 year of report, age, race, gender, foreignborn status, country of origin, city of residence, county of residence, history in a correctional
institution, occupation, death, homelessness, drug use, TB status, comorbid immunosuppressive
conditions (HIV, fibrotic lesions, diabetes, prolonged corticosteroid use, renal [kidney] failure,
blood disorder, cancer, low body weight, pulmonary silicosis, and gastrectomy or jejunoileal

10

The initial list generated in April 2007 contained 455 pulmonary cases were on the list. TBCP staff
cleaned the data in Fall 2007 such that in December 2007, there were 452 TB cases with pulmonary site of
disease.
11

According to the CDC’s Online Tuberculosis Information System (OTIS), 419 pulmonary TB cases were
counted in Connecticut from 2000 to 2005 (CDC 2008). The pulmonary case list in this study included 34
persons recorded as having pulmonary disease and disease involving an additional tissue site.

12

Source case number refers to the TB case identification number to which the individual was a contact.
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bypass), LTBI treatment prescribed, reason treatment of LTBI was not prescribed, treatment
status, total months of therapy, and total months of continuous therapy.

Protocol
Contact investigation data abstraction from TB case charts
Data were abstracted from pulmonary TB case charts to assess the completeness of
contact investigation data. Contact investigation reports, TB-5s, record information collected on
contacts at a fixed point in time. Therefore, they provide limited data on the treatment initiation
rate of contacts with LTBI and no information on therapeutic course. However, contact
investigation reports record important information on contact risk level and the components of
medical screening (tuberculin skin test, HIV test, and chest radiograph).
Of the 452 source cases on the pulmonary case list for the study period, 431 were located
and reviewed for information on contact investigations during May to September 2007.
Specifically, information from the TB-5 form and/or equivalent documents (e.g., spreadsheet,
detailed letter) was abstracted using the Pulmonary Case TB-5 Abstraction Form developed for
this study (Appendix G). Data on contacts that were abstracted from documents located in the TB
case chart were: date the form was sent by the TBCP to the agency conducting the investigation,
investigation setting, type of reporting agency, date the form was completed, total number of
contacts, and total number of PPD-positive (TST+) contacts. The following details were recorded
for each of the listed TST+ contacts: date of birth or age in years, gender, relationship of the
contact to the source case, TST result, HIV test result, chest radiograph information, drug
prescription status, reason for no prescription, and presence of medical provider information.
Information on contact investigations was recorded in an Excel spreadsheet on a passwordprotected computer at CTDPH. Descriptive analyses of these data were performed in Epi Info
version 3.4.1.
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Descriptive analysis of contacts with LTBI
Data on 1,294 TST+ persons were present in EXTRACT, the limited data set on persons
with LTBI extracted from TRIMS. Source TB case numbers were recorded for 1,293 (99.9%) of
contacts. The case numbers on the pulmonary case list were compared to the source case numbers
in EXTRACT. This demonstrated that 1,080 persons with LTBI were linked to 196 pulmonary
TB cases. Of these contacts, 755 initiated treatment for LTBI. Demographic and TB risk factor
data were analyzed using Epi Info and SPSS version 15.0.
Rate calculation
LTBI treatment completion rates were calculated using information on prescribed
medications and therapy duration in EXTRACT. Treatment completion was defined as record of
the minimum number of months of total therapy considered effective for the prescribed treatment
regimen and last treatment status recorded as “completed.” Drug regimen-specific treatment
completion rates were calculated by dividing the number of contacts who completed a specific
medication regimen by the number of contacts who were recorded as starting the regimen. These
rates were calculated for the 755 contacts who initiated treatment for LTBI. The overall treatment
completion rate was the result of dividing the total number of completers of LTBI treatment by
the total number of persons with latent infection that should have begun an LTBI treatment
regimen. The denominator for the overall LTBI treatment completion rate was 1,055, the number
of contacts who were potentially eligible for treatment. In addition, the rate of LTBI treatment
completion among contacts to culture-positive TB cases was calculated. The denominator for this
rate was 865.
Bivariate analysis and logistic regression
EXTRACT data on the age, race, gender, and TB risk factors of treatment initiators were
cross tabulated with treatment completion, a dichotomous variable, to determine the likelihood of
treatment completion associated with a specific contact characteristic. Odds ratios, Mantel24

Haenszel χ2 tests, Cornfield 95% confidence intervals, and two-tailed p values were generated by
Stat Calc and the “tables” command in Epi Info. The p value resulting from a Fisher exact test
was used for cross tabulations in which the expected value of a cell was less than five. Tests of
significance were conducted at the 0.05 level. Variables that demonstrated statistically significant,
associations with treatment completion were tested in an unconditional logistic regression model
using Epi Info.

Summary of Methods
The TBCP receives information on TB cases and their contacts with LTBI through
standard reporting forms that collect information on clinical indicators (e.g., TST, chest
radiograph), demographics, contact investigation, and therapeutic course. This information is
entered into electronic databases that can be queried to extract information on pulmonary TB
cases and their contacts with LTBI. Pulmonary TB case charts for 2000-2005 were identified
using a pulmonary case list generated by the TRIMS. Contact investigation data found on the
TB-5 forms in pulmonary case charts were abstracted using the Pulmonary Case TB-5
Abstraction Form. These data were used to describe the completeness of contact investigation
data that were collected during the study period. Information on pulmonary case contacts with
LTBI was provided by a limited data extract from TRIMS called EXTRACT. These data were
used to conduct descriptive analyses, calculate rates of LTBI treatment completion, and identify
predictors of treatment completion.

Human Subjects Research Approval
The University of Connecticut Health Center Institutional Review Board and the CTDPH
Human Investigations Committee approved this study. Certain data used in this publication were
obtained from the CTDPH. The author assumes full responsibility for analyses and interpretation
of these data.
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FINDINGS

Review of Contact Investigation Records
Completeness of contact investigations was assessed by review of pulmonary TB case
charts. The process and outcomes of abstracting contact investigation data from these charts are
summarized in Figure 1. Of the 452 TB cases on the pulmonary case list, 294 (65.0%) had AFBpositive sputum cultures.13 Four hundred and thirty-one (95.4%) pulmonary TB case charts were
located and reviewed from May to September 2007. Four hundred and sixty-five Pulmonary Case
TB-5 Chart Abstraction Forms were completed by reviewing TB-5 and/or equivalent documents
(e.g., detailed letter, spreadsheet). Overall, completed contact investigations were documented in
273 of the 431 (63.3%) pulmonary TB case charts reviewed. Contacts to 239 culture-positive
pulmonary TB cases were identified, representing 81.3% of the 294 culture-positive TB cases.
Documented investigations were recorded on 303 reports.14 Local health department staff
completed 235 (77.6%) of the documented contact investigations.
For 39 of the pulmonary TB case charts reviewed, documentation indicated that a contact
investigation request had been made, but no completed investigation report had been returned to
the TBCP or filed. For five pulmonary TB cases, a request for contact investigation was not made
of a local health department or another organization by the TBCP. There was no documentation
of contact investigation request or completion in 118 (27.4%) of the pulmonary case charts
reviewed. This suggests that an investigation request was either not made by the TBCP, or that

13

“Relative infectiousness has been associated with positive sputum culture results and is highest when the
smear results are also positive” (CDC 2005b).

14

For 30 pulmonary TB cases, documentation in charts indicated that the contact investigation entailed
screening of contacts in two different settings.
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contact investigation documents were not filed in case charts. In one instance, the researcher had
firsthand knowledge of a large contact investigation that had been completed by a local health
department and reported in detail to the TBCP. However, there was no indication of this in the
pulmonary TB case file.

Figure 1. Pulmonary TB Case Chart Abstraction Process and Outcomes
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Investigation settings
Contact investigation settings were classified as either community, congregate, more than
one, or unknown. Community settings included TB case households, residences of non-household
contacts, outpatient clinics, and workplaces. Most (87.8%) contact investigations were conducted
in community settings and involved screening of family members and regular acquaintances.
Congregate settings included adult day care, homeless shelter, prisons, inpatient hospitals,
hospice, long-term and skilled nursing care facilities, schools, and universities.

Table 3. Documented Contact Investigations, 2000 – 2005

Investigations
N (%)
242 (88.6)

Contacts
N (%)
3,141 (37.1)

Congregate settings

15 (5.5)

3,691 (43.6)

More than one setting

11 (4.0)

1,527 (18.0)

Unknown

5 (1.8)

111 (1.3)

273 (100.0)

8,470 (100.0)

Setting
Community

Total

Although investigations in congregate settings were less frequent than those in
community settings, they yielded 43.6% of contacts (Table 3). Seven investigations conducted in
schools or colleges yielded 3,318 (39.2%) of all documented contacts. Investigations in which
there were two or more settings were categorized as “More than one setting.” Seven of these
involved both a community and a congregate healthcare setting. “Unknown” refers to
investigations for which settings were not recorded and could not be inferred from documentation
reviewed in the pulmonary case charts. The largest single group of investigations, 58 (21.2%) of
investigations recorded in charts, was for pulmonary TB cases reported in 2000 (Figure 2).
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Figure 2. Contact Investigation Settings by Pulmonary TB Case Year, 2000 – 2005
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Documentation of medical screening
After contacts to infectious TB cases are identified, they should be screened for MTB
infection using the tuberculin skin test (TST). Contact investigation reports provide a limited
amount of information on contacts that was collected during a specific period. Contacts are
sometimes referred to their primary care physicians for follow-up on a positive TST. Therefore,
contact investigation reports may not contain information on the HIV test, chest radiograph,
physician, and/or LTBI treatment initiation status of contacts unless the investigator follows-up
with these individuals before returning TB-5 forms to the TBCP.
Pulmonary TB case chart review yielded 1,046 positive tuberculin skin test results among
the 8,594 contacts recorded in 170 (62.3%) of the 273 documented contact investigations. Table 4
shows the number of contact investigations, number of TST+ contacts, and average number of
TST+ contacts recorded for each type of contact investigation setting. Consistent with the large
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number of contacts screened during such events, the greatest average number of TST+ contacts
was for contact investigations conducted in congregate settings.

Table 4. TST+ Contacts by Contact Investigation Setting

Community

Investigations
N (%)
242 (88.6)

TST+ contacts
N (%)
634 (60.6)

TST+ contacts
Mean N
2.6

Congregate

15 (5.5)

295 (28.2)

19.7

More than one setting

11 (4.0)

76 (7.3)

6.9

Unknown

5 (1.8)

41 (3.9)

8.2

273 (100.0)

1,046 (100.0)

3.8

Setting

Total

Information on the type of contact (e.g., household, workplace, coworker) and risk level
(i.e. high, medium, or low) was inconsistently recorded on contact investigation reports. Risk
level was recorded in only 105 (34.5%) of contact investigation reports. Review of information
on the medical screening of contacts demonstrated that among the 1,046 TST+ contacts, an HIV
test was recorded for 12 (1.1%), a chest radiograph for 663 (63.4%), and a physician for 500
(47.8%). Prescription of LTBI treatment was recorded for 413 (39.5%).

Description of Contacts with LTBI
EXTRACT, the electronic data extracted from the TRIMS, contained information on
1,294 persons with LTBI in Connecticut who were associated with TB cases reported from 2000
to 2005 (Figure 3). Two hundred and nine (16.1%) were not linked to TB cases on the pulmonary
case list and therefore excluded. Five (0.4%) TST+ contacts were excluded because they were not
Connecticut residents.
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Figure 3. Summary of EXTRACT Data on Contacts with LTBI
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Table 5. Prevalence of Pulmonary TB Cases and Contacts with LTBI by Year

2000

Pulmonary Cases
N (%)
31 (15.8)

Contacts
N (%)
82 (7.6)

Average No. TST+
Contacts per Case
2.6

2001

42 (21.4)

301 (27.9)

7.2

2002

34 (17.3)

134 (12.4)

3.9

2003

35 (17.9)

149 (13.8)

4.3

2004

30 (15.3)

156 (14.4)

5.2

2005

24 (12.2)

258 (23.9)

10.8

Total

196 (100.0)

1,080 (100.0)

5.5

Year

One thousand and eighty (83.5%) of the persons with LTBI were contacts to 196
pulmonary TB cases (Table 5). Among the pulmonary TB cases, 147 (75%) had AFB-positive
sputum cultures. Eight hundred and sixty-seven (80.3%) of contacts were linked to these culturepositive pulmonary TB cases. The six-year average ratio of pulmonary TB cases to TST+
contacts was approximately 1:6. The greatest number of contacts, 301 (27.9%), was associated
with pulmonary TB cases recorded in 2001. The majority of contacts were 25 to 44 years old
(46.7%), classified as “White” (40.6%), and male (65.9%) (Table 6).
Place of residence has important implications for people’s access to health care and
resources that support healthy behaviors (Curtis and Jones 1998; Pickett and Pearl 2001; Krieger
et al. 2005). City and subsequently county of residence data were missing for 18.4% (199)
contacts. Most pulmonary TB cases (57.7%) and their contacts with LTBI (48.3%) resided in
Fairfield County (Table 7). The cities Bridgeport and Danbury accounted for 19.4% and 15.8% of
contacts to pulmonary TB cases, respectively. Rates of all pulmonary TB cases (n = 452) reported
during 2000 to 2005 and contacts with LBTI (n = 1,080) are listed by Connecticut town in
Appendix H.
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Table 6. Characteristics of Contacts with LTBI (n = 1,080)
Characteristics
Age group
0 – 4 years
5 – 14 years
15 – 24 years
25 – 44 years
45 – 64 years
65 years & older
Race
Asian
Black
Other*
White
Unknown
Gender
Male
Female

N (%)
32 (3.0)
49 (4.5)
273 (25.3)
504 (46.7)
174 (16.1)
48 (4.4)
135 (12.5)
158 (14.6)
8 (0.7)
439 (40.6)
340 (31.5)
712 (65.9)
368 (34.1)

*Includes the race categories American Indian, Multiracial, and Native Hawaiian.

Table 7. Contacts with LTBI by County of Residence

County

N (%)

6-year
Average
Population*

Rate per 100,000
Population

Fairfield

522 (48.3)

895,194

58.3

Hartford

191 (17.7)

867,736

22.0

Litchfield

25 (2.3)

186,568

13.4

Middlesex

14 (1.3)

159,781

8.8

New Haven

79 (7.3)

836,075

9.4

New London

35 (3.2)

262,934

13.3

Tolland

12 (1.1)

142,927

8.4

Windham

3 (0.3)

112,217

2.7

Unknown

199 (18.4)

-

-

1,080 (100.0)

3,463,431

31.2

Total

* U.S. Census population estimates
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In order to examine the geographic distribution of contacts with LTBI in the context of
the state’s socioeconomic trends, the five town groupings developed by the Center for Population
Research at the University of Connecticut (Levy et al. 2004) were applied. The five town groups
are based comparison of the equal share percentages (ESPs) of the 1990 and 2000 U.S. Census
measures of poverty, median family income, and population density.
Group 1, “Wealthy” towns like Westport and New Canaan, are characterized by low
poverty, “exceptionally” high income, and moderate population density. Group 2, “Suburban”
towns like Cheshire and Windsor, experience low poverty and above average income, and have
moderate population density. Group 3, “Rural” towns like North Stonington and Old Lyme, have
the lowest population density compared to other town groups, average income, and below
average poverty. Group 4, “Urban Periphery” towns like Manchester and Naugatuck, have high
population density, below average income, and average poverty. Group 5, “Urban Core” towns
like Bridgeport, Hartford, and New Haven, are characterized by the highest population density
and poverty share, and lowest income relative to towns in the other groups. Connecticut towns
and their group designations are listed in Appendix I. Most pulmonary TB cases (89.0%) and
contacts with LTBI (72.9%) resided in cities of the Urban Core and Urban Periphery (Table 8).

Table 8. Connecticut Town Group of Pulmonary TB Cases and Contacts with LTBI
Town – Group
Group1 – Wealthy
Group 2 – Suburban
Group 3 – Rural
Group 4 – Urban Periphery
Group 5 – Urban Core
Unknown
Total

Pulmonary Cases
N (%)
6 (3.0)
12 (6.0)
4 (2.0)
85 (43.5)
89 (45.5)
196 (100.0)
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Contacts with LTBI
N (%)
15 (1.4)
51 (4.7)
28 (2.6)
394 (36.5)
393 (36.4)
199 (18.4)
1,080 (100.0)

TB Risk Factors
The frequencies of TB risk factors among the contacts to pulmonary TB cases are
summarized in Table 9. A person with LTBI has increased risk of progression to active TB if s/he
has underlying clinical conditions, particularly ones associated with immunosuppression. The
TBCP records information the following TB risk factors which were categorized for analysis as
“immunosuppressive health conditions”: underweight (less than 10% of ideal), diabetes mellitus,
silicosis, chronic renal failure, gastrectomy, jejunoileal bypass, carcinoma of the head or neck,
HIV infection, prolonged corticosteroid use, fibrotic lesions, hematological (blood) disorders, and
“other” immunosuppressive conditions. Data on injection drug use (IDU), non-injection drug use,
alcohol abuse,15 corrections, homelessness, and foreign birth are also collected by the TB-86 and
recorded in TRIMS. The homeless, persons in correctional facilities, and persons not born in the
United States or its territories are at increased risk of exposure to MTB, and thus are more likely
to have LTBI than the general U.S. population.

Table 9. Frequency of TB Risk Factors for Contacts with LTBI (n = 1,080)

Contacts
N (%)
20 (1.9)

Missing data
N (%)
0 (0.0)

Injection drug use (IDU)

2 (0.2)

512 (47.4)

Non-injection drug use

7 (0.6)

526 (48.7)

102 (9.4)

314 (29.1)

Homelessness

4 (0.4)

504 (46.7)

Foreign birth

532 (49.3)

379 (35.1)

TB Risk Factor
Immunosuppressive health condition

Corrections facility

15

Alcohol abuse data was not extracted for this study.
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Of the 1,080 contacts to pulmonary TB cases, 20 (1.9%) had an immunosuppressive
health condition. No contact had more than one of these conditions. Two (0.2%) were users of
injection drugs and seven (0.6%), including one IDU, were users of non-injection drugs.
Information on injection drug use was missing for 512 (47.4%) of contacts. For non-injection
drug use, information on 526 (48.7%) of contacts was missing. One hundred and two (9.4%) of
contacts were in a correctional facility at the time that LTBI was reported. Four contacts (0.4%)
were homeless. There was no overlap between the correctional inmates and homeless contacts.
Birth in a foreign country was recorded for 532 (49.3%).
Increasingly, reported TB cases in the U.S. occur in the foreign born (CDC 2006d). In
Connecticut, approximately 12% of the population is foreign born (Appendix J). Imbedded within
country of birth data are issues related to primary language, immigration status, the recency of
entrance, and level of acculturation. But these data, which are correlated with health care access
and health outcomes (Lee et al. 2000; Stimpson and Urrutia-Rojas 2007), are not routinely
collected by the TBCP.

Table 10. Top Ten Reported Countries of Birth for Contacts with LTBI

Country
Missing
United States
Ecuador
Peru
India
Haiti
Brazil
Mexico
Puerto Rico
Poland
Total

N (%)
379 (35.1)
149 (13.8)
128 (11.9)
43 (4.0)
40 (3.7)
39 (3.6)
33 (3.1)
25 (2.3)
18 (1.7)
17 (1.6)
1,080 (100.0)

36

Among the 699 (64.7%) contacts for which birth country was recorded, the largest single
group was U.S.-born persons (Table 10). Country of birth information was missing for 379
(35.1%) contacts and often associated with pulmonary TB case year 2005. Country of birth data
were missing for 64.3% of contacts to 2005 pulmonary TB cases. Reported countries of birth,
summarized by WHO region and pulmonary TB case year, are presented in Appendix K.

Initiation of Treatment for LTBI
Of the 1,080 persons with LTBI who were recorded as contacts to pulmonary TB cases, 5
(0.5%) were treated for active TB, treatment status was unknown for one (0.1%), and 319
(29.5%) were not prescribed treatment for LTBI (Figure 3). Reasons for treatment
nonprescription were recorded for 312 contacts (Table 11). Provider decision was the most
frequent reason for not starting a LTBI treatment regimen (60%). “Other” reasons for treatment
nonprescription included: pregnancy, referral to another care provider before treatment started,
contact had active TB, contact left the state before treatment started, and negative result of a
second TST.
For nineteen contacts, “previous adequate treatment,”16 “case of TB,” “PPD negative,” or
“pregnancy” were listed as reasons why LTBI treatment was not prescribed. These exceptions to
LTBI treatment were consistent with the CDC guidelines. Persons being treated for active TB,
with unknown medication status, and a treatment contraindication were subtracted from the
number of contacts eligible for LTBI treatment. Thus, there were 1,055 potential contacts eligible
for treatment of LTBI.

16

Persons with previous adequate LTBI treatment do not require re-treatment unless they have an
immunosuppressive health condition.
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Table 11. Reasons LTBI Treatment Not Prescribed for Contacts

Reason

N (%)

Provider decision

192 (60.2)

Patient refused treatment

46 (14.4)

Lost before patient started medication

22 (6.9)

Evaluation not completed

12 (3.8)

Patient over age 35

12 (3.8)

Previous adequate treatment

12 (3.8)

Other

16 (5.0)

Missing

7 (2.2)

Total

319 (100.0)

Description of contacts on treatment
Seven hundred and fifty-five of the 1,080 contacts (69.9%) started treatment for LTBI
(Figure 3). Of these, 642 (85%) were contacts to culture-positive TB cases. Among these
contacts, most were 25 – 44 years old (48.2%), categorized “White” (50.3%), and male (66.4%)
(Table 12). Contacts with recorded TB risk factors frequently started LTBI treatment.
Specifically, 95% of those with an immunosuppressive condition; 100% of injection and noninjection drug users; 97% of persons in corrections; 50% of homeless; and 87.6% of foreign birth
initiated LTBI treatment. The most common TB risk factor recorded was foreign birth (Table 13).
After the United States, Ecuador was the most frequently recorded country of birth in the
treatment initiation group (Table 14). Approximately 60% of contacts who started treatment
resided in Fairfield County (Table 15). Most (89.0%) of them contacts lived in towns of the
Urban Periphery and Urban Core (Table 16 and Appendix I).
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Table 12. Characteristics of Contacts on LTBI Treatment (n = 755)

Characteristics
Age group
0 – 4 years
5 – 14 years
15 – 24 years
25 – 44 years
45 – 64 years
65 years & older
Race
Asian
Black
Other*
White
Unknown
Gender
Male
Female

N (%)
31 (4.1)
49 (6.5)
159 (21.1)
364 (48.2)
118 (15.6)
34 (4.5)
106 (14.0)
140 (18.5)
5 (0.7)
380 (50.3)
124 (16.4)
501 (66.4)
254 (33.6)

*Includes the race categories American Indian, Multiracial, and Native Hawaiian.

Table 13. Frequency of TB Risk Factors for Contacts on LTBI Treatment (n = 755)

TB Risk Factor
Immunosuppressive health condition
Injection drug use (IDU)
Non-injection drug use
Corrections facility
Homelessness
Foreign birth
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Contacts
N (%)
19 (2.5)
2 (0.3)
7 (0.9)
99 (13.1)
2 (0.3)
466 (61.7)

Missing data
N (%)
0 (0.0)
241 (31.9)
253 (33.5)
69 (9.1)
235 (31.1)
127 (16.8)

Table 14. Top Ten Reported Countries of Birth for Contacts on LTBI Treatment

Country
United States
Missing
Ecuador
Peru
Haiti
Brazil
India
Mexico
Puerto Rico
Poland
Total

N (%)
142 (18.8)
128 (16.9)
124 (16.4)
38 (5.0)
34 (4.5)
32 (4.2)
30 (4.0)
23 (3.0)
18 (2.4)
14 (1.9)
755 (100.0)

Table 15. Contacts on LTBI Treatment by County of Residence

County
Fairfield
Hartford
Litchfield
Middlesex
New Haven
New London
Tolland
Windham
Unknown
Total

N (%)
451 (59.7)
145 (19.2)
19 (2.5)
9 (1.2)
71 (9.4)
32 (4.2)
6 (0.8)
3 (0.4)
19 (2.5)
755 (100.0)
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Table 16. Contacts on LTBI Treatment by Connecticut Town Groups

Contacts on
LTBI Treatment
N (%)
13 (1.7)

Town Group
Group1 – Wealthy
Group 2 – Suburban

30 (4.0)

Group 3 – Rural

21 (2.8)

Group 4 – Urban Periphery

347 (46.0)

Group 5 – Urban Core

325 (43.0)

Unknown

19 (2.5)

Total

755 (100.0)

Presence of local public health services
Local health departments provide essential public health services (e.g., environmental
services, health education) to Connecticut residents. A local health department jurisdiction that is
larger than one town is classified as a health district. Districts must employ a full-time director of
health to enforce public health regulations and administer programs. A single town may employ a
part-time director of health. Health districts and departments employ public health nurses or
contract with visiting nurse associations to handle communicable disease issues like tuberculosis
(Frenette et al. 2004). Six hundred and fifty-two (86.4%) of those on an LTBI treatment regimen
resided in a town under the jurisdiction of a full-time local health department, 71 (9.4%) a health
district, and 13 (1.7%) a part-time local health department (Appendix L).17 As of September
2005, the TBCP listed eight full-time health departments (Bridgeport, Danbury, Greenwich,
Hartford, New Britain, Norwalk, Waterbury, and Stamford) as sites for comprehensive

17

The list of health departments is based on the directory of local health departments that was published
online by the CTDPH Office of Local Health Administration in July 2002. This resource is no longer
available on to the public on the Internet.
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tuberculosis services (CTDPH 2005b). Five hundred and twenty-eight (69.9%) contacts who
started treatment for LTBI resided in a city with a local health department clinic (Appendix L).

LTBI Treatment Completion
While the intended LTBI treatment regimen assigned to a contact is not recorded in
TRIMS, the type of drug or drugs, dosage(s), months of continuous therapy, and months of total
therapy are recorded. The gold standard for the treatment of LTBI is INH for nine months. The
minimum total number of months of INH therapy that is considered adequate is six.18 The
minimum number of total months of treatment that is adequate for both RIF and rifampin with
isoniazid (RIF+INH) is four. For RIF+PZA, the minimum number of total months on therapy is
two (Table 1). Thus, treatment completion was defined as the minimum number of months of
total therapy that is considered adequate and last therapeutic status recorded as “completed.”
Three hundred and fifty-two contacts met this definition of completed LTBI treatment (Figure 3).
Application of this definition excluded 13 contacts for which last treatment status was recorded as
“completed,” but who did not have recorded the total months of therapy considered adequate for
the medication prescribed.
Figure 4 shows the number of persons with LTBI who completed treatment by the year of
pulmonary TB case report or “pulmonary TB case year.” For contacts to pulmonary cases
reported in 2000, 41 of 74 (55.4%) completed treatment of LTBI. LTBI treatment completion was
52.7%, 41.8%, 41.3%, 49.6%, and 25.0% for contacts to pulmonary cases reported in 2001, 2002,
2003, 2004, and 2005, respectively (Figure 4). Of the 76 contacts to year 2005 pulmonary cases
who started LTBI treatment, 21 (27.6%) were recorded as “continuing” treatment and 16 (21.1%)

18

In a study of INH therapy completion and adverse medication effects, LoBue and Moser defined therapy
completion as at least six months of INH, even if nine months were prescribed (2003).
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were recorded as “start of therapy.” Given that EXTRACT was generated in 2007, these recorded
statuses are suspect.

Figure 4. LTBI Treatment Completion by Pulmonary TB Case Year

Overall, contacts to culture-positive TB cases accounted for 304 (86.4%) of persons who
completed treatment for LTBI. For pulmonary TB case year 2001, contacts to culture-positive
pulmonary TB cases represented 121 (88.3%) of contacts who completed treatment for LTBI
(Figure 5).
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Figure 5. LTBI Treatment Completion Among Contacts to Culture-Positive TB Cases by
Pulmonary TB Case Year

Health care providers frequently used the standard forms provided by the TBCP to report
persons with LTBI and update the treatment statuses of patients (Table 17). As resources and time
permitted, the TBCP generated a “tickler” report from the TRIMS system to identify contacts
who had begun treatment, but for whom information on treatment status had not been received for
at least six months. Follow-up was conducted with providers to collect missing information on
LTBI treatment statuses and the TRIMS was updated accordingly. The tickler report has not been
run regularly since 2004 (TBCP staff, personal communication).
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Table 17. Sources of Contact Therapeutic Status (n = 755)
Source
TB-86
TB-5
TB-6
TB-32
Other (unspecified)
Facility form*
Telephone call
Interagency referral
Tickler
Missing information
Total

Initial
N (%)
566 (73.6)
60 (7.9)
1 (0.1)
40 (5.3)
58 (7.7)
26 (3.4)
12 (1.6)
1 (0.1)
1 (0.1)
755 (100.0)

Final
N (%)
28 (3.7)
6 (0.8)
0 (0.0)
442 (58.5)
94 (12.5)
73 (9.7)
18 (2.4)
0 (0.0)
68 (9.0)
2 (0.3)
755 (100.0)

* Includes reports from the Connecticut Department of Corrections

INH regimens were the most frequently initiated (Table 18). Because B6 is a vitamin
supplement to INH therapy and not an antibiotic, the 328 INH regimens that included it were not
treated as distinct from INH-only regimens. The median duration of INH regimens was nine
months (range six to twelve months) with 53 (18.3%) of persons on INH completing six total
months of therapy and 167 (57.8%) completing nine months.
The least frequently recorded LTBI treatment regimens were rifampin with
pyrazindamide and ethambutol (RIF+PZA+EMB) and pyrazindamide with ethambutol
(PZA+EMB), each prescribed to one contact. These drug regimens are listed as “Other” in Table
16. The highest rate of LTBI treatment completion was among those on RIF+PZA. Overall,
46.6% of contacts who began an LTBI treatment regimen completed it. LTBI treatment
completion was most frequent among contacts on therapy regimens shorter than 6 months.
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Table 18. LTBI Treatment Regimen Completion Rates
Drug Regimen
INH
RIF
RIF+INH
RIF+PZA
Other
Total

Started
N
658
32
16
47
2
755

Completed
N
289
18
10
35
0
352

Completion rate
43.9%
56.3%
62.5%
74.5%
0.00
46.6%

Predictors of LTBI Treatment Completion
The potential predictors of LTBI treatment completion were assessed by cross tabulations
in Epi Info. The relationships between LTBI treatment completion and the following variables
were examined: 1) types of drugs initiated; 2) contact age, race, and gender; 3) contacts’ TB risk
factors; 4) geography of residence, and 5) country of birth.
Types of drugs initiated
Consistent with the high treatment completion rate observed, RIF+PZA therapy
demonstrated a significant association with treatment completion (p = 0.0001), with an odds ratio
(OR) of 3.60 (95% confidence interval [CI], 1.84 to 7.05). DOT was provided to 36 of the 47
persons on RIF+PZA. Among these contacts, 31 completed treatment for LTBI. Directly
observed therapy was an effective adjunct to any LTBI treatment regimen (p = 0.00000) with an
OR of 2.99 (95% CI, 1.76 to 5.08). DOT administration was recorded for 617 (81.7%) of contacts
who started treatment. Eighty-five received DOT and 65 (76.5%) of them completed treatment. In
contrast, of the 532 contacts who did not receive DOT, 277 (52.1%) completed treatment.
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Table 19. Treatment Regimens as Predictors of LTBI Treatment Completion
Drugs
INH
RIF
RIF+INH
RIF+PZA
Other

Complete
N (% at start)
289 (43.9)
18 (56.3)
10 (62.5)
35 (74.5)
0 (0.0)

Odds ratio

95% CI

p Value

0.42
1.50
1.93
3.60
0.00

0.27 – 0.66
0.73 – 3.06
0.70 – 5.38
1.84 – 7.05
Undefined

0.0001
0.2649
0.1985
0.0001
0.2846*

* Fisher exact

Contact age, race, and gender
Among these contact demographics, none were positively associated with LTBI
treatment completion (Table 20). Children under four years old were 2.2 times less likely to
complete treatment of LTBI (p = 0.0451). Of the 31 children in this age group, 100% were treated
with INH. Race data were missing for 124 (16.4%) of the contacts who initiated treatment.

Table 20. Contact Characteristics as Predictors of LTBI Treatment Completion
Complete
N (% at start)

Odds ratio

95% CI

p Value

0 – 4 years
5 – 14 years
15 – 24 years
25 – 44 years
45 – 64 years
65 years & older

9 (29.0)
27 (55.1)
78 (49.1)
159 (43.7)
61 (51.7)
18 (52.9)

0.45
1.44
1.13
0.80
1.27
1.30

0.21 – 1.00
0.80 – 2.57
0.80 – 1.61
0.60 – 1.06
0.86 – 1.89
0.65 – 2.60

0.0451
0.2188
0.4890
0.1183
0.2295
0.4501

Asian
Black
White
Other

48 (45.3)
58 (41.4)
178 (46.8)
1 (20.0)

1.00
0.81
1.16
0.28

0.65 – 1.51
0.56 – 1.19
0.84 – 1.61
0.03 – 2.55

0.9487
0.2884
0.3574
0.2317*

Female
Male

115 (45.3)
237 (47.3)

0.92
1.09

0.67 – 1.26
0.80 – 1.47

0.5976
0.5976

Characteristic
Age

Race

Gender

* Fisher exact
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TB risk factors
Among factors that place individuals with LTBI at increased risk for progression to
active tuberculosis, residence in a correctional facility had significant positive association with
LTBI treatment completion (Table 21). All 99 persons in corrections who initiated treatment for
LTBI received DOT (36.4% RIF+PZA and 64.6% INH).

Table 21. Contacts’ TB Risk Factors as Predictors of LTBI Treatment Completion
Complete
N (% at start)

Odds
ratio

95% CI

p Value

7 (36.8)

0.66

0.26 – 1.70

0.3870

0 (0.0)

0.00

Undefined

0.2963*

Non-injection drug use

2 (28.6)

0.47

0.09 – 2.46

0.3031*

Corrections facility

60 (60.6)

1.81

1.17 – 2.79

0.0007

Homelessness

0 (0.0)

0.00

Undefined

0.2936*

Foreign birth

220 (47.2)

1.20

0.84 – 1.73

0.3101

TB Risk Factors
Immunosuppressive
health condition
Injection drug use (IDU)

* Fisher exact

Geography of residence
Analysis demonstrated that residents of Litchfield County were less likely to have
completed treatment for LTBI compared to residents of other counties. New London County
residents were more likely to have completed treatment (Table 22). There was no predictive value
of UConn Center for Population Research town groups, type of local health department, or the
presence of a local public health clinic for treatment of TB and LTBI (Appendix M).
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Table 22. Contacts’ Counties of Residence as Predictors of LTBI Treatment Completion

Fairfield

Complete
N (% at start)
220 (48.8)

Hartford

59 (40.7)

0.74

0.51 – 1.07

0.1114

Litchfield

4 (21.1)

0.30

0.10 – 0.90

0.0238

Middlesex

0 (0.0)

0.00

Undefined

0.0034*

New Haven

34 (47.9)

1.06

0.65 – 1.73

0.8196

New London

21 (65.6)

2.26

1.08 – 4.77

0.0275

Tolland

4 (66.7)

2.31

0.42 – 12.67

0.2816*

Windham

1 (33.3)

0.57

0.05 – 6.33

0.5509*

County

Odds ratio

95% CI

p Value

1.25

0.93 – 1.69

0.1366

* Fisher exact

Country of birth
In this study, of the 196 pulmonary TB cases to whom contacts with LTBI were linked,
149 (76.0%) were foreign-born. Among the 755 contacts to pulmonary TB cases who initiated
treatment for LTBI, 466 (61.7%) were foreign born. Three hundred and seventy-six (49.8%) of
them had the same country of birth as the pulmonary TB cases to whom they were linked.
LTBI treatment completion by country of birth was examined using the six World Health
Organization regions and the top ten countries of birth for contacts who initiated LTBI treatment.
Bivariate analyses demonstrated no statistically significant associations between the WHO
regions and LTBI treatment completion. Likewise, no significant associations between individual
countries of birth and completion of LTBI treatment were observed. (Appendix N).
To explore if language played a role in LTBI treatment completion, contacts with
recorded countries of birth in which Spanish is the official language (Argentina, Dominican
Republic, Ecuador, El Salvador, Guatemala, Honduras, Peru, and Puerto Rico) were combined.
There were 219 contacts for which Spanish (or a Spanish dialect) may have been the primary
language. In this group, 46.1% completed LTBI treatment. Persons of foreign origin for whom
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Spanish may be the primary language were 3.4 times less likely to have completed LTBI
treatment compared to speakers of English and other languages (OR 0.29; 95% CI 0.19 to 0.43; p
< 0.0000).

Table 23. WHO Regions of Origin as Predictors of LTBI Treatment Completion
WHO Region
Africa

Complete
N (% at start)
7 (36.8)

Odds ratio

95% CI

p Value

0.68

0.26 – 1.74

0.4197

Americas

216 (45.8)

0.97

0.68 – 1.40

0.8814

Southeast Asia

13 (34.2)

0.59

0.30 – 1.18

0.1349

Europe
Eastern
Mediterranean
Western Pacific

21 (48.8)

1.13

0.61 – 2.11

0.6924

3 (50.0)

1.18

0.24 – 5.89

0.5778*

28 (57.1)

1.63

0.90 – 2.94

0.1013

* Fisher exact

Model for Predicting LTBI Treatment Completion
Evaluation of the relationship between LTBI treatment completion and LTBI treatment
regimens, contact demographics, TB risk factors, geography of residence, and country of origin
demonstrated that treatment with INH, treatment with RIF+PZA, DOT, residence in New London
county, and history of corrections were positively associated with LTBI treatment completion at
the p < 0.05 level. Age less than 4 years, and residence in Litchfield County were negatively
associated with LTBI treatment completion at the p < 0.05 level. Unconditional logistic
regression models were fitted using these variables. Model 1 (Figure 5) explains the treatment
outcomes for 563 (74.6%) of the persons who started treatment for LTBI (-2*log-likelihood =
743.21; Likelihood ratio [χ2, 7df] = 30.21; p = 0.0001).
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Figure 6. Multivariate Logistic Regression – Model 1
Term

Odds
ratio

Corrections

0.4038

0.1571

DOT

4.3616

Coefficient

SE

1.0379

-0.9069

0.4817

-1.8827

0.0597

1.6887

11.2647

1.4728

0.4841

3.0423

0.0023

Litchfield County 0.2465

0.0644

0.9431

-1.4003

0.6846

-2.0455

0.0408

New London
County

1.5342

0.6513

3.6142

0.428

0.4372

0.9791

0.3275

Age 0 - 4 years

0.3113

0.1184

0.8181

-1.1671

0.493

-2.3671

0.0179

RIF+PZA

1.2017

0.3973

3.6346

0.1838

0.5647

0.3255

0.7448

INH

0.6121

0.3189

1.1747

-0.4909

0.3326

-1.4759

0.14

*

*

*

0.6213

0.3235

1.9203

0.0548

CONSTANT

Convergence:
Iterations:
Final -2*Log-Likelihood:
Cases included:

Test Statistic
Score: 28.4737
Likelihood Ratio: 30.2076

95% CI

Z- statistic p-Value

Converged
5
743.2116
563

D.F.
7
7

P-Value
0.0002
0.0001

According to this model, DOT was a strong predictor of treatment completion while
residence in Litchfield County and age less than or equal to four years were strong predictors of
treatment noncompletion. However, of the 31 children aged four years and younger who began
INH, therapy was discontinued for 12 (38.7%) with the reason for stopping therapy recorded as
“not TB” in reference to the source pulmonary TB case. However, only contacts to pulmonary TB
cases were included in EXTRACT. Another model was constructed which excluded the youngest
age group (Figure 7).
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Figure 7. Multivariate Logistic Regression – Model 2

Term

Odds
ratio

Corrections

0.4548

0.1787

DOT

3.9410

Coefficient

SE

1.1572

-0.7880

0.4765

-1.6536

0.0982

1.5337

10.1267

1.3714

0.4815

2.8483

0.0044

Litchfield County 0.2580

0.0675

0.9865

-1.3548

0.6843

-1.9798

0.0477

New London
County

1.4766

0.6378

3.4185

0.3897

0.4283

0.9100

0.6328

RIF+PZA

1.3731

0.4608

4.0913

0.3170

0.5571

0.5691

0.5693

INH

0.6953

0.3698

1.3073

-0.3634

0.3221

-1.1281

0.2593

*

*

*

0.4580

0.3103

1.4763

0.1399

CONSTANT

Convergence:
Iterations:
Final -2*Log-Likelihood:
Cases included:

Test Statistic
Score: 22.6819
Likelihood Ratio: 24.1417

95% CI

Z- statistic p-Value

Converged
5
749.2776
563

D.F.
6
6

P-Value
0.0009
0.0005

Model 2 was still statistically significant (-2*log-likelihood = 749.28; Likelihood ratio
[χ2, 7df] = 24.14; p = 0.0005). DOT as a predictor of treatment completion and residence in
Litchfield County as a predictor of treatment noncompletion were still observed in this reduced
model.

Incomplete Treatment for LTBI
Of the 755 contacts that began treatment for LTBI, 403 did not meet the definition of a
completed LTBI treatment regimen. Last treatment status was recorded as “lost or incomplete for
175 (43.3%) of these contacts. This translates to an attrition of 23.2% of those who began LTBI
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treatment. For 24 (6.0%) of contacts who did not complete LTBI treatment, “not TB” was
recorded as the last treatment status; however, all were contacts to a person on the pulmonary TB
case list. Further examination of how incomplete treatment for LTBI is recorded in TRIMS, while
beyond the scope of this study, is warranted.

Table 24. Last Treatment Statuses for Contacts Who Did Not Complete LTBI Treatment

Lost or incomplete

Contacts
N (%)
175 (43.4)

Unknown status – admin closeout

45 (11.2)

Continuing

43 (10.7)

Start of therapy

35 (8.7)

Reaction/toxicity

32 (7.9)

Not TB

24 (6.0)

Refused/uncooperative/noncompliant

18 (4.5)

Completed

13 (3.2)

Stopped for medical reason

8 (2.0)

Died

4 (1.0)

Restarted

4 (1.0)

Moved

2 (0.5)

Status

Total

403 (100.0)

Summary of Findings
Review of pulmonary TB case charts demonstrated that contact investigations were not
conducted for all TB cases with primary site of disease recorded as “pulmonary” from 2000 to
2005. The majority, 241 (83.7%), of documented contact investigations identified contacts to
culture-positive pulmonary TB cases. Local health departments completed most (80.9%) of
contact investigation reports. While most investigations were conducted in the community, most
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reported contacts were screened in congregate settings. Information on contact risk level was
recorded in only 34.5% of all contact investigation reports. Data recorded on medical screening
demonstrated that information on HIV status was not routinely collected.
Analysis of the electronic data extract from TRIMS, EXTRACT, demonstrated that
among persons with LTBI who were contacts to pulmonary TB cases reported during 2000 to
2005, 69.9% (755 of 1,080) began LTBI treatment. Among the 29.5% who did not begin LTBI
treatment, “provider decision” was the most frequently recorded reason for treatment not being
started. Most of the contacts who did begin LTBI treatment were 25 – 44 years old (48.2%), male
(66.4%), classified as “White” (50.3%) and of foreign-birth (61.7%). Fifty to 100% of individuals
with a specific TB risk factor like an underlying immunosuppressive condition began treatment
for LTBI. Similar to the distribution of Connecticut pulmonary TB cases, the majority of persons
on LTBI treatment resided in Fairfield County (59.7%) and cities of the Urban Periphery (46.0%)
and Urban Core (43.0%).
INH was the most frequently initiated LTBI treatment regimen (87.1% [658 of 755]).
However, contacts on shorter drug regimens completed therapy at a greater rate than contacts on
INH. Regimen-specific LTBI treatment completion rates among persons on RIF+PZA, a regimen
no longer recommended, were highest (74.5% [35 of 47]). DOT enhanced the likelihood of
RIF+PZA and INH treatment regimens; however, it was most frequent in correctional facilities,
not community settings.
Overall, the treatment completion rate for contacts to pulmonary TB cases reported in
Connecticut during 2000 to 2005 was 33.4% (352 of 1,055). For contacts to culture-positive
pulmonary TB cases, the LTBI treatment completion rate was 35.1% (304 of 865). The
percentages of contacts that initiated and completed treatment for LTBI are listed by selected
variables in Appendix O.
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DISCUSSION

Tuberculosis is a long-standing public health concern. In our efforts to eradicate the
“white plague”, we have made microbiological and pharmacological breakthroughs, constructed
medical care centers, and developed effective models of care that have facilitated the control of
many other communicable diseases. Nationwide infectious disease surveillance contributed to our
ability to quell TB resurgence in the United States. However, the tuberculosis pandemic, drugresistant tuberculosis, and disparities in tuberculosis prevalence among ethnic and racial minority
population groups frustrate TB elimination efforts in the United States.
According to the CDC, there are 10 – 15 million people with LTBI in the United States.
On average, 10% of them will develop active disease during their lifetimes. Given the slow
decline of the nationwide TB rate, the increased burden of the disease in the foreign born and
persistent disparities in TB rates between persons classified as “whites” and racial/ethnic
minorities, strategies to prevent persons with LTBI from progressing to active disease are of
increasing importance. Reducing the number of persons at risk for progressing to active disease
by increasing the number of persons who complete treatment for LTBI can significantly reduce
the burden of tuberculosis in the United States (Sterling et al. 2006). Identifying factors that are
positively associated with LTBI treatment completion will enhance the nationwide TB control
effort.
In this study, data collected by the Connecticut Health Department Tuberculosis Control
Program were used to describe contact investigations and contacts with latent tuberculosis
infection. By determining the odds of treatment completion associated with specific contact
characteristics, predictors of LTBI treatment completion in the study population were identified.
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Also, the rate of LTBI treatment completion among Connecticut residents who are contacts to
pulmonary TB cases was calculated and compared to a Healthy People 2010 target.
Although it was not inclusive of all pulmonary TB cases of the study period (due to
missing/misfiled charts), the review of contact investigation reports in the charts of pulmonary
TB cases from 2000 to 2005 demonstrates the volume of effort expended by the TBCP and its
partners to identify and screen people who may have been exposed to a pulmonary TB case.
Identifying and screening contacts to infectious pulmonary TB cases were a TBCP priority.
Among the 272 documented contact investigations that were reviewed, 88.6% identified contacts
to culture-positive pulmonary TB cases.
However, of the 452 TB cases with the primary disease site recorded as “pulmonary,”
only 431 (95.3%) charts were located. Also, there was no evidence that a contact investigation
had been conducted for 118 pulmonary TB cases. This suggests that an investigation request was
either never made by the TBCP, and/or that investigation-related documents were not filed with
TB case charts. The missing/misfiled pulmonary TB case charts and investigation reports indicate
that improved documentation of contact investigation requests and record keeping are needed.
Programs with limited resources like the TBCP should assign priorities to contacts,
focusing their prevention efforts on those at high and medium risk of infection. The pulmonary
case chart review demonstrated that risk level was recorded on only 34.5% of contact
investigation reports. Part of risk assessment is measuring environmental exposure. There is no
indication on the Tuberculosis Contact Investigation Report (TB-5) of how investigators are to
systematically classify exposures in the manner suggested by the Guidelines for the Investigation
of Contacts of Persons with Infectious Tuberculosis (NTAC and CDC 2005). This may have
contributed to the underreported contact risk level information. Missing risk information
increases the likelihood of screening large amounts of people, some of whom have had limited or
no exposure to a TB case and would be classified as being at low or no risk of infection.
56

Establishing criteria for assigning contact risk level can improve allocation of limited TBCP and
local health department resources.
Review of medical screening data from contact investigation reports demonstrated that
HIV status was only recorded for 1.1% of the 1,046 TST+ contacts documented. This suggests
that contacts who had skin tests were not routinely asked about this important risk factor for
progression to active TB. It is important to determine if this is an ongoing issue.
Analyses of EXTRACT demonstrated that most persons with LTBI reported as contacts
to TB cases were male (65.9%), aged 25 to 44 years (46.7%), and classified as “White” (40.6%).
While age and gender data were frequently recorded, race data were unknown for 31.5% of
contacts. Race data were collected using categories inconsistent with those defined in the Office
of Management and Budget (OMB) Revisions to the Standards for the Classification of Federal
Data on Race and Ethnicity (OMB 1997) (Appendix P). There was no “Native Hawaiian or Other
Pacific Islander” category for race. Accurate and complete information on race data that are
comparable to other data sets (e.g., U.S. Census data) are increasingly important as public health
programs focus on health disparities elimination.
Almost one-third (31.5%) of information on contact country of birth was missing.
Foreign-born persons are at risk for developing TB, particularly if they are from countries with
high TB burdens. From 2000 to 2004, 62% of TB cases in Connecticut were among foreign-born
persons (Condren et al. 2006). According to the American Community Survey, Fairfield and
Hartford counties were home to most foreign-born persons in Connecticut (Appendix J, Figure
J2). In this study population, these counties were recorded as areas of residence for 66% of
contacts with LTBI (Table 7). More complete country of birth information is needed in order to
identify populations that would benefit from enhanced local outreach. Moreover, contacts with
LTBI who originated from countries in which Spanish is the official language were 3.4 times less
likely to have completed treatment for LTBI compared to other contacts with LTBI. Low English
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proficiency (LEP) may have contributed to this outcome. Data on primary language are needed to
not only to enhance service provision, but also to monitor how CTDPH is taking steps to improve
the access of LEP populations to services.19
Consistent with the literature (Menzies et al. 2004; Lardizabal et al. 2006; Marks et al.
2000; Blumberg, Leonard, Jr., and Jasmer 2005), this study demonstrates that short therapeutic
courses and DOT were associated with higher LTBI treatment completion rates. In this study,
RIF+ PZA had the greatest LTBI treatment regimen-specific completion rate (74.5%). The short,
two-month duration of the regimen and the large proportion of recipients on DOT contributed to
this. While the four-month RIF regimen was not positively associated with LTBI treatment
completion in this cohort, it has demonstrated promise as an alternative to the preferred ninemonth course of INH.20
Among contacts who initiated INH for treatment of LTBI, 57.8% completed nine months
of therapy while 28% completed six to eight months. INH taken for nine months confers greater
protection against progression to active TB than a six-month INH regimen (IUAT Committee on
Prophylaxis 1982). There were no data on prescribed treatment duration. Treatment completion
among those assigned to a six-month INH regimen was not calculated. Were contacts completing
less than the optimal duration of INH therapy because they were assigned shorter regimens or
because they discontinued treatment? Such information would be useful for program evaluation
and enhancement of outreach to high-risk populations.

19

Recipients of Federal financial assistance like public health agencies must take reasonable steps to
provide LEP persons with meaningful opportunity to participate in DHHS-funded programs. Failure to do
so may constitute a violation of Titile VI of the Civil Rights Act of 1964, which prohibits conduct that has a
disproportionate effect on LEP persons. Such conduct is the same as national-origin discrimination (DHHS
2003).

20

Lardizabal and colleagues (2006) found that patients on four months of RIF were 5.1 times more likely to
complete treatment than patients on nine months of INH (p < 0.0001).
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The observed differences in treatment completion, specifically residence in Litchfield
County and New London County, may be related to the prevalence of LTBI treatment services in
specific areas. However, for this sample of contacts who began treatment for LTBI, persons who
lived in towns with local health department clinics were not more likely to complete treatment
than contacts who lived elsewhere. This may be the result of differences in the local availability
of primary care and/or infectious diseases specialists. EXTRACT did not contain data on the
location of the health care providers who were monitoring LTBI treatment. Availability of and
access to services are areas for future research.
In their studies of contact investigation outcomes, Marks and colleagues (2000) and
Reichler and colleagues (2002b) determined that 74% and 89% of TST+ contacts initiated LTBI
treatment, respectively. Similarly, in this study, 71.6% (755 of 1,055) of the contacts potentially
eligible for treatment started therapy. Marks’ and Reichler’s research teams found that among
TST+ contacts who started LTBI treatment, 56% and 51% completed therapy, respectively. In
this study, of the 755 TST+ contacts who initiated therapy, 46.6% (352) completed therapy.
Overall, the LTBI treatment completion rate for contacts to pulmonary TB cases reported
in Connecticut during 2000 to 2005 was 33.4% (352 of 1,055). For contacts to infectious
pulmonary TB cases, the LTBI treatment completion rate was 35.1% (304 of 865). Healthy
People 2010 objective 14-13 is to increase the proportion of contacts and other high-risk persons
with LTBI who complete a course of treatment to 85% (DHHS 2000). This objective was
achieved for neither contacts with TB risk factors nor contacts without underlying risk factors.
Among persons in this sample with TB risk factors, 35% (7 of 20) with an immunosuppressive
health condition, 0% (0 of 2) IDU, 28.6% (2 of 7) non-IDU, 58.8% (60 of 102), 0% (0 of 4)
homeless, and 41.3% (220 of 532) of foreign-born persons completed treatment for LTBI
(Appendix O).
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For this study population, the national objective of 85% LTBI treatment completion
would have been achieved if an additional 545 contacts had completed treatment. Potential
completers of LTBI treatment may have been among those for whom treatment was not
prescribed. “Provider decision” was recorded as a reason that LTBI treatment was not prescribed
for 8.2% (192 of 1,055) of contacts with LTBI who were potential treatment candidates. Because
the actual reasons for such decisions were not recorded, it is not possible to determine if they
were in accordance with the CDC guidelines. Additional information from health care providers
is needed to determine what they think LTBI treatment contraindications are.
In 1993, the cost of tuberculosis diagnosis and treatment in a public health system in the
United States was $68,578 (Wurtz and White 1999). Adjusting for inflation (U.S. Department of
Labor 2008), the cost was $92,678 per case in 2005. Assuming that the lifetime risk of
progression to active TB in persons with LTBI is 10%, and treatment efficacy of 50% to 100%
for all LTBI treatment regimens, 18 to 35 new TB cases were prevented in Connecticut residents
as a result of treatment completion by the 352 contacts to pulmonary cases recorded from 2000 to
2005. This is equivalent to approximately 3 to 6 fewer TB cases per year. Using the inflationadjusted cost of TB diagnosis and treatment, the reduction in Connecticut TB cases translated to
decreased healthcare costs of approximately $278,000 - $556,000 per year.

Limitations
This was a retrospective study of paper and electronic records maintained by state public
health agency. These records were produced through routine program activities, and therefore
were formatted to fit specific business objectives, not research ones. Nonstandard contact
investigation reports often did not contain all of the data elements of the TB-5. Because
pulmonary TB case charts and contact investigation requests and reports were missing/misfiled,
the number of contacts screened and reported as TST+ for the study period was likely
undercounted.
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Data from the electronic surveillance system, TRIMS, were used to describe contacts
with LTBI and calculate treatment completion rates. The validity of electronic data was not
assessed by comparison with data collection forms. Data on ethnicity was not included in the
database abstract, thus the relationship between ethnicity and LTBI treatment completion could
not be assessed. A data entry backlog may have contributed to an undercount of persons who
completed LTBI treatment. While data on the types of medications prescribed were available,
there were no data on the prescribed length of treatment. Thus, the odds of treatment completion
for a shorter regimen of INH could not be reliably calculated. Missing data on race, country of
birth, and TB risk factors biased odds ratios, thus influencing variable inclusion in multivariate
analyses. Missing data were most often associated with pulmonary case year 2005.
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CONCLUSION

The work done by the Connecticut Tuberculosis Control Program and its community and
health care partners to identify, screen, and treat contacts with LTBI is a large, complex
undertaking. This study demonstrated that the rate of LTBI treatment completion among
Connecticut residents who were contacts to pulmonary TB cases reported during 2000 to 2005
was 32.6%, well below the 85% objective defined in Healthy People 2010. In order to achieve
this national objective, the number of persons with LTBI who start and complete treatment must
be increased.
Improved data collection and ongoing analysis of contact investigation data and LTBI
treatment completion rates among recent contacts to pulmonary TB cases can enhance the efforts
of the Connecticut Department of Public Health Tuberculosis Control Program. The quality and
content of contact investigation reports and contact treatment data must be improved so that
accurate assessment of program performance may be conducted.

Recommendations
Recommendations for achieving the Healthy People 2010 objective of 85% of contacts
completing treatment for LTBI in Connecticut are:
1) Develop written procedures for routine TBCP operations. Specifically, request for contact
investigations, follow-up on contact investigation reports, filing, and data entry are areas
that may be improved by clear instructions and training for all permanent or temporary
staff (e.g. student interns).
2) Program evaluation to improve program performance. Activities related to contact
investigations and treatment of contacts with LTBI need to be identified, described in
detail, and assessed for their effectiveness. Evaluation would identify the most effective
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strategies to achieve national, state, and local performance goals and allow tracking of
program performance over time. The DTBE recommends program evaluation using the
CDC framework for program evaluation in public health (DTBE 2005). The
Massachusetts Department of Public Health has used this framework to assess its TB
contact investigation protocols and processes (Logan et al. 2003).
3) Create a continuous improvement program. The initial foci of improvement efforts would
be reasons for LTBI treatment non-completion, specifically not starting LTBI treatment
because of “provider decision” and loss to follow-up after treatment has begun. Perform a
benchmark review of other state public health department activities related to increasing
LTBI treatment initiation and completion in New England. Create solutions to these
issues that would work in Connecticut. Establish best practices to ensure long-term
success of planned improvement activities. The Mississippi State Health Department
achieved an increase from 79.7% to 96.5% LTBI treatment completion after
implementing a quality improvement program with continuous performance monitoring
(Fos et al. 2005).
4) Assign an epidemiologist to manage contact investigation reports, generate the tickler
report from TRIMS, perform timely follow-up on missing data (e.g., race, country of
birth), and routinely review treatment completion data to describe progress toward
program goals.
5) Establish criteria for assigning a risk level to contacts that takes into account time and
environment of exposure in accordance with the Guidelines for the Investigation of
Contacts of Persons with Infectious Tuberculosis: Recommendations from the National
Tuberculosis controllers Association and CDC (CDC 2005b).
6) Offer annual training of local health department staff, visiting nurses, and others who
perform contact investigation. Educate TBCP partners about the standard classification of
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risk. Emphasize the importance of collecting and recording contacts’ demographic and
HIV status data.
7) Update data collection forms and electronic databases to collect and record race and
ethnicity information consistent with the Revisions to the Standards for the Classification
of Federal Data on Race and Ethnicity.
8) Conduct qualitative assessments to inform program tools and activities. For example,
focus group discussions with local health staff who frequently conduct contact
investigations could yield information on improving the design of the TB-5 and
enhancing interaction with TBCP staff during large or complex contacts investigations. A
survey of clinicians could identify the most frequent reasons that providers decide not to
prescribe LTBI treatment and present opportunities for educating clinicians about the
current LTBI treatment guidelines.
9) Include a field in TRIMS to record the prescribed duration of LTBI treatment. This will
make it possible to determine the number of persons completing adequate versus optimal
treatment for LTBI with INH.
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APPENDIX A
Abbreviations and Glossary

Abbreviations
ACET

Advisory Council for the Elimination of Tuberculosis

AFB

acid-fast bacilli

ALA

American Lung Association

B6

pyridoxine

BCG

Bacille Calmette-Guérin

CDC

U.S. Centers for Disease Control and Prevention

CTDPH

Connecticut Department of Public Health

DHHS

U.S. Department of Health and Human Services

DOT

directly observed therapy

DTBE

CDC Division of Tuberculosis Elimination

ELISA

enzyme-linked immunosorbent assay

EMB

ethambutol

EXTRACT

electronic data on contacts

IDSA

Infectious Diseases Society of America

IDU

injection drug use

INF-γ

interferon-gamma

INH

isoniazid

IOM

Institute of Medicine

IUAT

International Union Against Tuberculosis

LHD

local health department

LTBI

latent tuberculosis infection

MDG

Millennium Development Goal

MDR-TB

multidrug-resistant tuberculosis

MTB

Mycobacterium tuberculosis complex

NTCA

National Tuberculosis Controllers Association
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APPENDIX A
Abbreviations and Glossary
(continued)
Abbreviations
OL-15C

Laboratory Report of Significant Findings

OMB

Office of Management and Budget

OTA

U.S. Congress Office of Technology Assessment

PD-23

Reportable Diseases Confidential Case Report Form

PPD

purified protein derivative

PZA

pyrazinamide

QFT-G

Quantiferon gold test

RIF

rifampin or rifamycin

SLD

second line drug

TB

tuberculosis

TBCP

Connecticut Department of Public Health Tuberculosis Control Program

TEAC

Connecticut Tuberculosis Elimination Advisory Committee

TIMS

Tuberculosis Information Management System

TRIMS

Tuberculosis Registry and Information Management System

TST

tuberculin skin test

TST+

positive tuberculin skin test result

TST-

negative tuberculin skin test

WHO

World Health Organization
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APPENDIX A
Abbreviations and Glossary
(continued)

Terms
Contact

Refers to a person who has been exposed to M. tuberculosis infection by
sharing an air space with someone with infectious TB (CDC 2005b).

Induration

Firms bump that result from skin test reaction to tuberculin antigen.
Measured transversely and recorded in millimeters (mm). The measurement
is compared to guidelines to determine if the skin test result is positive or
negative. (CDC 2005b).

Infectious TB

TB disease of the lungs or throat that has a great potential to cause
transmission to other forms of active tuberculosis (CDC 2005b).

Mantoux

Tuberculin skin test method used in the United States. Entails injection of
purified protein derivative (PPD) under top layer of skin of the inside of the
forearm. A measurable induration results two to three days later, indicating
MTB infection.

Smear

Laboratory technique for preparing a sputum specimen so that the bacteria
can be seen using a microscope. The sputum is spread onto a glass slide,
dried, and treated with a chemical stain. The slide is viewed under a
microscope and the visible bacteria are counted. The number of stained
organisms corresponds to the infectiousness of the TB case (CDC 2005b).

Sputum

Lung mucus coughed up by a TB case. This mucus is tested to confirm
pulmonary TB disease. (CDC 2005b).
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Reportable Disease Confidential Case Report Form (PD-23)
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APPENDIX C
Laboratory Report of Significant Findings (OL-15C)
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APPENDIX D
Tuberculosis Contact Investigation Report (TB-5)
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APPENDIX E
Tuberculosis Surveillance Report (TB-86)
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APPENDIX F
Tuberculosis Therapy and Follow-up Form (TB-32)
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APPENDIX G
Pulmonary Case TB-5 Abstraction Form
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APPENDIX H
Rates of Reported Pulmonary TB and LTBI in Contacts per 100,000 in
Connecticut by Town, 2000 – 2005

Town

Average
Mid-Year
Population,
2000 to
2005*

Pulmonary
Cases
N (%)

Pulmonary
Case Rate
per 100,000

Contacts
with
LTBI
N (%)

LTBI Rate
per 100,000

Population > 100,000
Bridgeport

139,487

69 (15.3)

49.5

209 (19.4)

149.9

Hartford

124,438

60 (13.3)

48.2

80 (7.4)

64.3

New Haven

124,566

36 (8.0)

28.9

25 (2.3)

20.0

Stamford

119,127

35 (7.7)

29.3

53 (4.9)

44.4

Waterbury

108,139

13 (2.9)

12.0

14 (1.3)

12.9

Population 75, 000 to 99,999
Danbury

76,797

34 (7.5)

44.3

171 (15.8)

221.6

New Britain

71,594

16 (3.5)

22.3

50 (4.6)

69.8

Norwalk

78,818

12 (2.7)

15.2

32 (3.0)

38.1

Population 50,000 to 74,999
Bristol

60,629

6 (1.3)

9.9

6 (0.6)

9.9

Fairfield

57,875

6 (1.3)

10.4

12 (1.1)

10.4

Greenwich

61,845

5 (1.1)

8.1

7 (0.6)

8.1

Hamden

57,722

3 (0.7)

5.2

4 (0.4)

5.2

Manchester

55,181

3 (0.7)

5.4

2 (0.2)

5.4

Meriden

58,533

5 (1.1)

8.5

16 (1.5)

8.5

Milford

53,530

2 (0.4)

3.7

6 (0.6)

3.7

West Hartford

61,334

4 (0.9)

7.2

5 (0.5)

6.5

West Haven

52,736

11 (2.4)

20.8

1 (0.1)

20.9

* Town population estimates for 2000 – 2005 published by the CTDPH (2001; 2002; 2003; 2004; 2005; 2006b).
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APPENDIX H
Rates of Reported Pulmonary TB and LTBI in Contacts per 100,000 in
Connecticut by Town, 2000 – 2005
(continued)

Town

Average
Mid-Year
Population,
2000 to
2005*

Pulmonary
Cases
N (%)

Pulmonary
Case Rate
per 100,000

Contacts
with
LTBI
N (%)

LTBI Rate
per 100,000

Population 25,000 to 49,999
Branford

28,913

3 (0.7)

10.4

1 (0.1)

3.5

Cheshire

29,015

2 (0.4)

6.9

0 (0.0)

0.0

East Hartford

49,531

15 (3.3)

30.3

20 (1.8)

40.4

East Haven

28,504

1 (0.2)

3.5

0 (0.0)

0.0

Enfield

45,360

2 (0.4)

4.4

1 (0.1)

2.2

Glastonbury

32,702

0 (0.0)

0.0

1 (0.1)

3.0

Groton

40,232

4 (0.9)

9.9

1 (0.1)

2.5

Middletown

46,144

2 (0.4)

4.3

11 (1.0)

27.0

Naugatuck

31,478

0 (0.0)

0.0

2 (0.2)

6.3

New London

26,113

4 (0.9)

15.3

14 (1.3)

53.4

New Milford

28,034

4 (0.9)

14.3

7 (0.6)

24.8

Newington

29,552

4 (0.9)

13.5

9 (0.8)

30.4

Norwich

36,326

6 (1.3)

16.5

15 (1.4)

41.3

Shelton

38,710

6 (1.3)

15.5

5 (0.5)

12.9

South Windsor

25,150

3 (0.7)

11.9

1 (0.1)

4.0

Southington

41,021

0 (0.0)

0.0

1 (0.1)

2.4

Stratford

43,553

7 (1.5)

16.1

10 (0.9)

20.0

Torrington

35,672

1 (0.2)

2.8

16 (1.5)

44.7

Trumbull

34,880

5 (1.1)

14.3

6 (0.6)

17.0

Wallingford

43,942

3 (0.7)

6.8

1 (0.1)

2.3

Westport

26,332

3 (0.7)

11.4

1 (0.1)

3.8

Wethersfield

26,315

0 (0.0)

0.0

1 (0.1)

3.8

Windsor

28,418

5 (1.1)

17.6

4 (0.4)

14.1

* Town population estimates for 2000 – 2005 published by the CTDPH (2001; 2002; 2003; 2004; 2005; 2006b).
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APPENDIX H
Rates of Reported Pulmonary TB and LTBI in Contacts per 100,000 in
Connecticut by Town, 2000 – 2005
(continued)

Town

Average
Mid-Year
Population,
2000 to
2005*

Pulmonary
Cases
N (%)

Pulmonary
Case Rate
per 100,000

Contacts
with LTBI
N (%)

LTBI Rate
per 100,000

4 (0.4)
0 (0.0)
4 (0.4)
5 (0.5)
0 (0.0)
3 (0.3)
1 (0.1)
0 (0.0)
1 (0.1)
1 (0.1)
0 (0.0)
0 (0.0)
0 (0.0)
12 (1.1)
1 (0.1)
1 (0.1)
1 (0.1)
0 (0.0)
0 (0.0)
0 (0.0)
2 (0.2)
2 (0.2)
4 (0.4)
0 (0.0)
0 (0.0)
2 (0.2)
0 (0.0)
0 (0.0)
1 (0.1)
4 (0.4)
1 (0.1)
1 (0.1)
0 (0.0)

21.3
0.0
21.1
27.1
0.0
18.7
7.4
0.0
8.0
5.5
0.0
0.0
0.0
53.1
5.2
5.2
5.1
0.0
0.0
0.0
13.3
8.3
21.8
0.0
0.0
10.5
0.0
0.0
5.3
22.4
4.3
8.2
0.0

Population 12,500 to 24,999
Ansonia
Avon
Berlin
Bethel
Bloomfield
Brookfield
Clinton
Darien
Derby
East Lyme
Farmington
Guilford
Ledyard
Mansfield
Monroe
Montville
New Canaan
North Branford
North Haven
Orange
Plainfield
Ridgefield
Rocky Hill
Seymour
Simsbury
Southbury
Suffield
Tolland
Waterford
Wilton
Windham
Windsor Locks
Wolcott

18,784
16,570
19,001
18,447
19,880
16,022
13,452
20,092
12,545
18,237
24,325
21,951
14,985
22,619
19,367
19,401
19,802
14,129
23,551
13,536
15,053
24,088
18,309
15,837
23,507
19,072
14,173
14,026
19,045
17,897
23,095
12,200
15,835

2 (0.4)
1 (0.2)
0 (0.0)
0 (0.0)
1 (0.2)
2 (0.4)
0 (0.0)
2 (0.4)
1 (0.2)
0 (0.0)
2 (0.4)
1 (0.2)
2 (0.4)
2 (0.4)
0 (0.0)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
3 (0.7)
1 (0.2)
1 (0.2)
1 (0.2)
0 (0.0)
1 (0.2)
1 (0.2)
1 (0.2)
3 (0.7)
2 (0.4)
0 (0.0)
1 (0.2)

10.6
6.0
0.0
0.0
5.0
12.5
0.0
10.0
8.0
0.0
8.2
4.6
13.3
8.8
0.0
5.2
5.1
7.1
4.2
7.4
6.6
12.5
5.5
6.3
4.3
0.0
7.1
7.1
5.3
16.8
8.7
0.0
6.3

* Town population estimates for 2000 – 2005 published by the CTDPH (2001; 2002; 2003; 2004; 2005; 2006b).
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APPENDIX H
Rates of Reported Pulmonary TB and LTBI in Contacts per 10,000 in
Connecticut by Town, 2000 – 2005
(continued)

Town

Average
Mid-Year
Population,
2000 to 2005*

Pulmonary
Cases
N (%)

Pulmonary
Case Rate
per 100,000

Contacts with
LTBI
N (%)

LTBI Rate
per
100,000

Population < 12,499
Brooklyn

7,453

1 (0.2)

13.4

0 (0.0)

0.0

Burlington

8,675

1 (0.2)

11.5

0 (0.0)

0.0

Coventry

12,161

1 (0.2)

8.2

0 (0.0)

0.0

East Windsor

10,129

1 (0.2)

9.9

1 (0.1)

9.9

Easton

7,450

2 (0.4)

26.8

0 (0.0)

0.0

Griswold

11,017

0 (0.0)

0.0

2 (0.2)

18.2

Lebanon

7,094

1 (0.2)

14.1

0 (0.0)

0.0

Old Saybrook

10,490

0 (0.0)

0.0

2 (0.2)

19.1

Oxford

10,666

0 (0.0)

0.0

1 (0.1)

9.4

Prospect

9,066

1 (0.2)

11.0

0 (0.0)

0.0

Weston

10,212

2 (0.4)

19.6

0 (0.0)

0.0

Winchester

10,848

2 (0.4)

18.4

1 (0.1)

9.2

Woodbury

9,498

1 (0.2)

10.5

1 (0.1)

10.5

Woodstock

7,608

1 (0.2)

13.1

0 (0.0)

0.0

Missing

—

0 (0.0)

—

199 (18.4)

—

Total

—

452 (100.0)

—

1,080 (100.0)

—

* Town population estimates for 2000 – 2005 published by the CTDPH (2001; 2002; 2003; 2004; 2005; 2006b).
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APPENDIX I
UConn Center for Population Research Town Groups
Group 1, Wealthy: Darien, Easton, Greenwich, New Canaan, Ridgefield, Weston, Westport, and
Wilton
Group 2, Suburban: Avon, Berlin, Bethany, Bethel, Bethlehem, Bolton, Bridgewater,
Brookfield, Burlington, Canton, Cheshire, Chester, Clinton, Columbia, Cromwell, Durham,
East Granby, Ellington, Essex, Fairfield, Farmington, Glastonbury, Granby, Guilford,
Haddam, Harwinton, Hebron, Killingworth, Lyme, Madison, Marlborough, Middlebury,
Monroe, New Fairfield, New Hartford, Newtown, North Branford, North Haven, Old
Saybrook, Orange, Oxford, Prospect, Redding, Roxbury, Salem, Shelton, Sherman,
Simsbury, South, Southbury, Southington, Suffield, Tolland, Trumbull, Wallingford,
Washington, Watertown, Windsor, Wolcott, Woodbridge, and Woodbury
Group 3, Rural: Andover, Ashford, Barkhamsted, Beacon Falls, Bozrah, Brooklyn, Canaan,
Canterbury, Chaplin, Colchester, Colebrook, Cornwall, Coventry, Deep River, East Haddam,
East Hampton, East Lyme, East Windsor, Eastford, Franklin, Goshen, Griswold, Hampton,
Hartland, Kent, Killingly, Lebanon, Ledyard, Lisbon, Litchfield, Mansfield, Middlefield,
Montville, Morris, New Milford, Norfolk, North Canaan, North Stonington, Old Lyme,
Plainfield, Plymouth, Pomfret, Portland, Preston, Putnam, Salisbury, Scotland, Sharon,
Somers, Sprague, Stafford, Sterling, Stonington, Thomaston, Thompson, Union, Voluntown,
Warren, Waterford, Westbrook, Willington, Winchester, and Woodstock
Group 4, Urban Periphery: Ansonia, Bloomfield, Branford, Bristol, Danbury, Derby, East
Hartford, East Haven, Enfield, Groton, Hamden, Manchester, Meriden, Middletown, Milford,
Naugatuck, Newington, Norwalk, Norwich, Plainville, Rocky Hill, Seymour, Stamford,
Stratford, Torrington, Vernon, West Hartford, Wethersfield, Windham, and Windsor Locks
Group 5, Urban Core: Bridgeport, Hartford, New Britain, New Haven, New London,
Waterbury, and West Haven

Source: Levy et al. 2004: 11
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APPENDIX J
The Connecticut Foreign-Born Population

Figure J1. Estimated Percent of the Population that is Foreign Born –
Connecticut and the United States, 2001 - 2006
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APPENDIX J
The Connecticut Foreign-Born Population
(continued)

Figure J2. Estimated Percent of the Connecticut Population that is Foreign Born –
Counties in Connecticut, 2001 - 2004
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APPENDIX K
Contacts’ Countries of Birth and WHO Regions
Countries of Birth for Contacts with LTBI by WHO Region (n = 1,080)
Africa
N (%)
Europe
N (%)
Congo
6 (0.6)
Belgium
1 (0.1)
Ghana
5 (0.5)
Bosnia and Herzegovina
6 (0.6)
Nigeria
3 (0.3)
Bulgaria
1 (0.1)
Rwanda
1 (0.1)
France
1 (0.1)
Zaire
1 (0.1)
Germany
1 (0.1)
Zambia
5 (0.5)
Hungary
1 (0.1)
Italy
1 (0.1)
Latvia
3 (0.3)
Americas
Argentina
3 (0.3)
Macedonia
1 (0.1)
Brazil
33 (3.1)
Norway
1 (0.1)
Colombia
11 (1.0)
Poland
17 (1.6)
Costa Rica
1 (0.1)
Portugal
9 (0.8)
Dominica
2 (0.2)
Turkey
3 (0.3)
Dominican Republic
10 (0.9)
Turkmenistan
1 (0.1)
Ecuador
128 (11.9)
Ukraine
3 (0.3)
El Salvador
7(0.6)
United Kingdom
1 (0.1)
Guatemala
12 (1.1)
Yugoslavia
2 (0.2)
Guyana
1 (0.1)
Haiti
39 (3.6)
Eastern Mediterranean
Honduras
9 (0.8)
Bahrain
1 (0.1)
Jamaica
9 (0.8)
Egypt
2 (0.2)
Mexico
25 (2.3)
Iran
3 (0.3)
Peru
43 (4.0)
Pakistan
2 (0.2)
Puerto Rico
18 (1.7)
Trinidad and Tobago
1 (0.1)
Western Pacific
USA
149 (13.8)
Cambodia
7 (0.6)
14
(1.3)
Virgin Islands
2 (0.2)
China
Japan
7 (0.6)
Laos
13 (1.2)
Southeast Asia
Bangladesh
3 (0.3)
Mongolia
1 (0.1)
India
40 (3.7)
Philippines
5 (0.5)
Republic of Korea
4 (0.4)
Taiwan
4 (0.4)
Nepal
3 (0.3)
Vietnam
13 (1.2)
Unknown
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381 (35.3)

APPENDIX K
Contacts’ Countries of Birth and WHO Regions
(continued)
Table K1. WHO Regions of Birth for Contacts with LTBI by Year
WHO Region
2000 2001 2002 2003 2004 2005 TOTAL
Africa

7

1

2

6

4

1

21

Row %

33.3

4.8

9.5

28.6

19

4.8

100.0

Col %

8.5

0.3

1.5

4

2.6

0.4

1.9

Americas

56

151

68

82

102

44

503

Row %

11.1

30

13.5

16.3

20.3

8.7

100.0

Col %

68.3

50.2

50.7

55

65.4

17.1

46.6

6

5

3

10

3

23

50

Row %

12

10

6

20

6

46

100.0

Col %

7.3

1.7

2.2

6.7

1.9

8.9

4.6

7

21

4

3

11

7

53

Row %

13.2

39.6

7.5

5.7

20.8

13.2

100.0

Col %

8.5

7

3

2

7.1

2.7

4.9

0

0

3

0

0

5

8

Row %

0

0

37.5

0

0

62.5

100.0

Col %

0

0

2.2

0

0

1.9

0.7

4

28

7

2

11

12

64

Row %

6.3

43.8

10.9

3.1

17.2

18.8

100.0

Col %

4.9

9.3

5.2

1.3

7.1

4.7

5.9

2

95

47

46

25

166

381

Row %

0.5

24.9

12.3

12.1

6.6

43.6

100.0

Col %

2.4

31.6

35.1

30.9

16

64.3

35.3

82

301

134

149

156

258

1,080

Row %

7.6

27.9

12.4

13.8

14.4

23.9

100.0

Col %

100.0

100.0

100.0

100.0

100.0

100.0

100.0

Southeast Asia

Europe

Eastern Mediterranean

Western Pacific

Missing

TOTAL
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APPENDIX L
Contacts on Treatment for LTBI by City of Residence and Local Health Department

Town

Local Health Department

Contacts on
LTBI Treatment
N (%)

Part-time Director of Health
Brookfield
East Lyme
Griswold
New Canaan
Newington

Town of Brookfield
Town of East Lyme
Town of Griswold
Town of New Canaan
Town of Newington

3 (0.4)
1 (0.1)
2 (0.3)
1 (0.1)
6 (0.8)

Full-time Director of Health
Bethel
Bridgeport*
Clinton
Danbury*
East Hartford
Fairfield
Greenwich*
Hartford*
Manchester
Meriden
Middletown
Milford
New Britain*
New Haven
New London
New Milford
Norwalk*
Ridgefield
Stamford*
Stratford
Waterbury*
West Haven
Wilton
Windsor
*

Bethel Health Department
Bridgeport Health Department
Town of Clinton
Danbury Health and Housing Department
East Hartford Health Department
Fairfield Health Department
Greenwich Health Department
Hartford Health Department
Manchester Health Department
Meriden Department of Health
Middletown Health Department
Milford Health Department
New Britain Health Department
New Haven Health Department
New London Health Department
New Milford Health Department
Norwalk Health Department
Town of Ridgefield
Stamford Health Department
Stratford Health Department
Waterbury Health Department
West Haven Health Department
Wilton Health Department
Windsor Health Department

Denotes location of public health TB clinic
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5 (0.7)
173 (22.9)
1(0.1)
161 (21.3)
18 (2.4)
9 (1.2)
6 (0.8)
61 (8.1)
1 (0.1)
14 (1.9)
8 (1.1)
6 (0.8)
39 (5.2)
23 (3.0)
14 (1.9)
7 (0.9)
27 (3.6)
2 (0.3)
47 (6.2)
8 (1.1)
14 (1.9)
1 (0.1)
3 (0.4)
4 (0.5)

APPENDIX L
Contacts on Treatment for LTBI by City of Residence and Local Health Department
(continued)

Town

Local Health
Department Name

Contacts on
LTBI
Treatment
N (%)

Health District with Full-time Director of Health
Bristol
Rocky Hill
Wethersfield
East Haven
Mansfield
Groton
Waterford
Ansonia
Derby
Naugatuck
Shelton
East Windsor
Enfield
Windham
Plainfield
Oxford
Southbury
Woodbury
Hamden
Torrington
Monroe
Trumbull
Montville
Norwich
West Hartford
Westport
Missing
Total

Bristol-Burlington Health District
Central Connecticut Health District
Central Connecticut Health District
East Shore Health District
Eastern Highlands Health District
Ledge Light Health District
Ledge Light Health District
Naugatuck Valley Health District
Naugatuck Valley Health District
Naugatuck Valley Health District
Naugatuck Valley Health District
North Central Health District
North Central Health District
North Central Health District
Northeast District Department of Health
Pomperaug Health District
Pomperaug Health District
Pomperaug Health District
Quinnipiack Health District
Torrington Area Health District
Trumbull-Monroe Health District
Trumbull-Monroe Health District
Uncas Health District
Uncas Health District
West Hartford-Bloomfield Health District
Westport-Weston Health District
—
—
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5 (0.7)
3 (0.4)
1 (0.1)
1 (0.1)
6 (0.8)
1 (0.1)
1 (0.1)
4 (0.5)
1 (0.1)
2 (0.3)
1 (0.1)
1 (0.1)
1 (0.1)
1 (0.1)
2 (0.3)
1 (0.1)
1 (0.1)
1 (0.1)
3 (0.4)
11 (1.5)
1 (0.1)
3 (0.4)
1 (0.1)
12 (1.6)
5 (0.7)
1 (0.1)
19 (2.5)
755 (100.0)

APPENDIX M
Selected Variables as Predictors of LTBI Treatment Completion

Table M1. Town Groups as Predictors of LTBI Treatment Completion
Town Group
Group1 – Wealthy
Group 2 – Suburban
Group 3 – Rural
Group 4 –
Urban Periphery
Group 5 – Urban Core

Complete
N (% at start)
6 (46.2)
13 (43.3)
9 (42.9)

Odds ratio

95% CI

p Value

0.98
0.87
0.86

0.33 – 2.95
0.42 – 1.82
0.36 – 2.06

0.9739
0.7141
0.7271

174 (50.1)

1.31

0.98 – 1.75

0.0691

141 (43.4)

0.79

0.59 – 1.06

0.1198

Table M2. Local Health Department Characteristics as
Predictors of LTBI Treatment Completion
Characteristic
Part-time
All full-time
District
Non-district
Clinic site

Complete
N (% at start)
9 (69.2)
334 (46.2)
32 (45.1)
302 (46.3)
251 (47.5)
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Odds ratio

95% CI

p Value

2.62
0.67
0.93
0.91
1.13

0.80 – 8.57
0.33 – 1.36
0.57 – 1.52
0.60 – 1.39
0.83 – 1.54

0.0995
0.2649
0.7831
0.6742
0.4422

APPENDIX N
Top Ten Countries of Birth as Predictors of LTBI Treatment Completion

Complete
N (% at start)

Odds ratio

95% CI

p Value

USA

61 (43.0)

0.83

0.57 – 1.22

0.3316

Missing

64 (50.0)

1.12

0.75 – 1.67

0.5663

Ecuador

63 (50.8

1.22

0.82 – 1.83

0.3073

Peru

12 (31.6)

0.51

0.24 – 1.08

0.0566

Haiti

19 (55.9)

1.48

0.70 – 3.11

0.2684

Brazil

20 (62.5)

1.96

0.90 – 4.33

0.0660

India

10 (33.3)

0.56

0.25 – 1.21

0.1368

Mexico

8 (34.8)

0.60

0.23 – 1.53

0.2480

Puerto Rico

8 (44.4)

0.91

0.33 – 2.54

0.8514

Poland

5 (35.7)

0.63

0.16 – 2.12

0.4092

Country
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APPENDIX O

LTBI Treatment Initiation (SOT) and Completion (COT) Among
Contacts to Pulmonary TB Cases

Table O1. SOT and COT by Pulmonary TB Case Year

Year

Contacts
n = 1,080

SOT
n = 755

COT
n = 352

% Completed
Therapy

2000

82

74

41

50.0

2001

301

260

137

45.5

2002

134

91

38

27.6

2003

149

120

49

32.9

2004

156

134

68

43.6

2005

258

76

19

7.4

Table O2. SOT and COT for Contacts to Culture-Positive TB Cases
by Pulmonary TB Case Year

Year

Contacts
n = 865

SOT
n = 642

COT
n = 304

% Completed
Therapy

2000

72

66

37

51.4

2001

258

226

121

46.9

2002

107

79

31

29.0

2003

133

108

42

31.6

2004

114

99

55

48.2

2005

181

64

18

9.9
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APPENDIX O
LTBI Treatment Initiation (SOT) and Completion (COT) Among
Contacts to Pulmonary TB Cases
(continued)

Table O3. SOT and COT by Age Group

Age group

Contacts
n = 1,080

SOT
n = 755

COT
n = 352

% Completed
Therapy

0 – 4 years

32

31

9

28.1

5 – 14 years

49

49

27

55.1

15 – 24 years

273

159

78

28.6

25 – 44 years

504

364

159

31.5

45 – 64 years

174

118

61

35.1

65 years & older

48

34

18

37.5

Table O4. SOT and COT by Race

Race

Contacts
n = 740

SOT
n = 631

COT
n = 285

% Completed
Therapy

Asian

135

106

48

35.6

Black

158

140

58

36.7

Other*

8

5

1

12.5

White

439

380

178

40.5

* Includes the race categories American Indian, Multiracial, and Native Hawaiian.
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APPENDIX O
LTBI Treatment Initiation (SOT) and Completion (COT) Among
Contacts to Pulmonary TB Cases
(continued)

Table O5. SOT and COT by Connecticut County of Residence

County

Contacts
n = 881

SOT
n = 736

COT
n = 343

% Completed
Therapy

Fairfield

522

451

220

42.1

Hartford

191

145

59

30.9

Litchfield

25

19

4

16.0

Middlesex

14

9

0

0.0

New Haven

79

71

34

43.0

New London

35

32

21

60.0

Tolland

12

6

4

33.3

Windham

3

3

1

33.3

Table O6. SOT and COT by TB Risk Factors

Contacts

SOT

COT

% Completed
Therapy

20

19

7

35.0

2

2

0

0.0

7

7

2

28.6

102

99

60

58.8

Homelessness

4

2

0

0.0

Foreign birth

532

466

220

41.3

TB Risk factors
Immunosuppressive
health condition
Injection drug use (IDU)
Non-injection drug use
Corrections facility
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APPENDIX P
Federal Ethnicity and Race Categories

Ethnicity
Hispanic or Latino
Not Hispanic or Latino

Race
American Indian or Alaska Native
Asian
Black or African American
Native Hawaiian or Other Pacific Islander
White

Source: Office of Management and Budget 1997
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